

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

INTERVENTIONAL PROCEDURES PROGRAMME

Interventional procedure overview of transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Benign prostatic hyperplasia is a non-cancerous enlargement of the prostate. It can block or narrow the tube (urethra) that urine passes through to leave the body, causing urination problems. During this procedure, heated water vapour is injected into the prostate using a special probe that is passed up the urethra. The heat from the vapour destroys some of the prostate tissue, reducing its size.

Contents

- [Introduction](#)
- [Description of the procedure](#)
- [Efficacy summary](#)
- [Safety summary](#)
- [The evidence assessed](#)
- [Validity and generalisability of the studies](#)
- [Existing assessments of this procedure](#)
- [Related NICE guidance](#)
- [Additional information considered by IPAC](#)
- [References](#)
- [Literature search strategy](#)
- [Appendix](#)

Introduction

The National Institute for Health and Care Excellence (NICE) prepared this interventional procedure overview to help members of the interventional procedures advisory committee (IPAC) make recommendations about the safety

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

and efficacy of an interventional procedure. It is based on a rapid review of the medical literature and specialist opinion. It should not be regarded as a definitive assessment of the procedure.

Date prepared

This overview was prepared in November 2017 and was updated in April 2018.

Procedure name

- Transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Specialist societies

- British Association of Urological Surgeons
- Royal College of Surgeons.

Description of the procedure

Indications and current treatment

Lower urinary tract symptoms caused by benign prostatic hyperplasia commonly affect men over 50. Stromal and epithelial cells increase in number, causing the prostate to increase in size. It often occurs in the periurethral region of the prostate, with large discrete nodules compressing the urethra. Symptoms include hesitancy during micturition, interrupted or decreased urine stream (volume and flow rate), nocturia, incomplete voiding and urinary retention.

Mild symptoms are usually managed conservatively. Drugs may also be used, such as alpha blockers and 5-alpha-reductase inhibitors. If other treatments have not worked, there are a range of surgical options that may be considered including transurethral resection of the prostate (TURP), transurethral vaporisation, holmium laser enucleation, insertion of prostatic urethral lift implants, prostatic artery embolisation or prostatectomy (see the NICE guideline on [lower urinary tract symptoms in men](#)). Potential complications of some of these surgical procedures include bleeding, infection, urethral strictures, incontinence and sexual dysfunction.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

What the procedure involves

Transurethral water vapour ablation is usually done as day-case surgery using local anaesthetic including a peri-prostatic block, and sometimes sedation.

A device similar to a rigid cystoscope is advanced into the prostatic urethra. Under direct visualisation, a retractable needle is inserted into the prostate and water vapour (at a temperature of about 103 degrees centigrade) is delivered for 8 to 10 seconds. At the same time, saline irrigation is used to cool and protect the surface of the urethra. Conductive heat transfer disrupts cell membranes in the prostate, leading to rapid cell death and necrosis. The needle is retracted and repositioned several times so that thermoablation can be repeated in different areas of the gland, including the median lobe. The aim is to reduce the size of the prostate, leading to improvement in lower urinary tract symptoms 1 to 3 months after treatment, without impairing sexual function.

Patients may have to take antibiotics and have a urinary catheter for some days after the procedure. Some activities, including sexual intercourse, should be avoided for up to 1 month.

Outcome measures

International Prostate Symptom Score (IPSS)

The IPSS is a validated questionnaire often used to assess symptoms of benign prostatic hyperplasia (BPH). It is also referred to as the American Urological Association BPH Symptom Score Index. It includes questions on 7 dimensions: feeling of incomplete bladder emptying, frequency, intermittency, urgency, weak stream, straining and nocturia (referring to the previous month) and each involving assignment of a score from 1 to 5. Higher scores represent worse symptoms. In general, an IPSS symptom score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms. An additional question asks men how they feel about their BPH symptoms and the response yields a score for quality of life (ranging from 0 to 6, with 0 representing 'delighted' and 6 representing 'terrible').

International Index of Erectile Function (IIEF)

The IIEF is a validated 15-item questionnaire used to assess men's sexual function in 5 domains: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. Each domain has its own score range and lower scores represent greater dysfunction:

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

- Erectile function score: range 0 to 30 (scores of 24 or less represent increasing dysfunction)
- Orgasmic function score: range 0 to 10 (scores of 8 or less represent increasing dysfunction)
- Sexual desire score: range 0 to 10 (scores of 8 or less represent increasing dysfunction)
- Intercourse satisfaction score: range 0 to 15 (scores of 12 or less represent increasing dysfunction)
- Overall satisfaction score: range 0 to 10 (scores of 8 or less represent increasing dysfunction).

Benign prostatic hyperplasia impact index (BPHII)

The BPHII is a validated self-administered questionnaire used to assess the impact on quality of life caused by urinary symptoms in men with BPH. It is formed of 4 questions about urinary problems during the past month regarding physical discomfort, worry about health, how bothersome symptoms are, and whether the symptoms are interfering with usual activities. Scores range from 0 (no symptoms) to 13 (severe symptoms).

Overactive bladder (OAB) symptom score

The OAB symptom score uses a self-reported questionnaire to quantify OAB symptoms: daytime frequency, night-time frequency, urgency and urgency incontinence. Patients are asked to rate their symptom severity on a Likert scale with the maximum (worst) scores of 2, 3, 5, and 5. The overall score is a sum of all individual questions scores and ranges from 0 to 15. A more severe OAB is indicated by a higher score. The scoring system is designed to place more weight on urgency and urgency incontinence than on frequency.

Overactive Bladder Questionnaire Short Form (OAB-q SF)

The OAB-q SF is a self-administered patient-reported outcomes tool with 2 scales assessing symptom 'bother' and health-related quality of life (HRQL) in patients with OAB. The instrument consists of 19 items with 6 items assessing symptom bother (unique dimension) and 13 items assessing health-related quality of life (coping, concern, sleep and social interaction). The subscales are summed and transformed into scores ranging from 0 to 100. The symptom-bother and the HRQL scales are inversely related: a high symptom-bother score

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

indicates greater symptom severity and a high HRQL scale score indicates better quality of life.

Male Sexual Health Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD)

The MSHQ is a validated questionnaire used to assess the degree of ejaculatory dysfunction in men. Its long form includes 3 domains: erection scale (3 items), ejaculation scale (7 items) and sexual satisfaction scale (6 items). There are 9 additional items (2 items measuring bothersome symptoms linked to erection and ejaculation, and 7 items measuring sexual activity and desire). The MSHQ short form (MSHQ-EjD-SF) includes 2 domains: ejaculatory function (3 items) and bother/satisfaction (1 item).

International Continence Society male incontinence score - short form (ICSMIS-SF)

The ICSMIC-SF is a validated, self-administered questionnaire used to assess the impact of urinary incontinence on quality of life. The instrument is composed of 11 items, 5 assessing voiding and 6 assessing incontinence. The total score is obtained from the simple sum of each question's individual score. Higher scores represent worse quality of life.

Uroflowmetry:

Uroflowmetry is used to measure the maximum urinary flow rate (Qmax) and voided volume. Flow-rate measurements may be inaccurate if the voided volume is less than 150 millilitres (mL). Qmax values below the threshold of 15 mL/second suggest bladder outlet obstruction.

Efficacy summary

Overall benign prostatic hyperplasia clinical progression

In a comparative study of 1,269 patients with benign prostatic hyperplasia (BPH) who had thermal therapy (n=129), or doxazosin (n=367), or finasteride (n=390), or a combination of doxazosin and finasteride (n=383), the rate of BPH clinical progression (defined as a 4-point or greater IPSS increase from baseline for acute urinary retention, UTI, urosepsis, or incontinence; or a serum creatinine increase of at least 1.5 mg/dl to at least 50% above baseline) was 0.3 per 100 person-years for thermal therapy, compared with 1.7 per 100 person-years for doxazosin alone or in combination, and 1.5 per 100 person-years for finasteride. After 3 years, the rate of clinical progression was less than

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

1% (1/129) for thermal therapy compared with 5% (18/368) for doxazosin, 4% (16/394) for finasteride and 5% (18/384) for the combination group⁹.

International prostate symptom score (IPSS)

In a randomised control trial (RCT) and case series of 197 patients with BPH, mean IPSS was statistically significantly lower in patients who had water vapour ablation (WVA, 10.8 ± 6.5) compared with the sham group (17.5 ± 7.6 , $p < 0.0001$) at 3-month follow-up. In the same study, people having sham were invited to crossover to the treatment group and paired outcomes were compared at 3-month follow-up, then patients were followed up for 1 year. Mean IPSS scores were statistically significantly lower in the crossover group after WVA (9.8 ± 6) compared with the paired sham (18 ± 7.6 , $p = 0.0004$) at 3-month follow-up, and mean IPSS scores were still statistically significantly reduced from baseline assessment (8.6 ± 6.6 , $p < 0.0001$) at 1-year follow-up. In the same study, 136 men who had WVA were followed-up for 3 years. Mean preoperative IPSS statistically significantly reduced from baseline to 1-year follow-up (10.3 ± 6.7 , $p < 0.0001$), which was maintained at 3-year follow-up (10.4 ± 6.1 , $p < 0.0001$)¹⁻⁴.

In a case series of 131 patients who had WVA, mean IPSS statistically significantly reduced from baseline to 3 to 6 month follow-up (9.8 ± 6.9 , $p < 0.0001$) and the improvement was sustained at 12-month follow-up (10.1 ± 7.2 , $p < 0.0001$)⁵.

In a case series of 65 patients who had WVA, mean IPSS statistically significantly reduced from baseline to 1-month follow-up (14.8 ± 8.4 , $p < 0.001$) and at 2-year follow-up (9.6 ± 6.5 , $p < 0.001$)⁶⁻⁸.

In the comparative study of 1,269 patients, thermal therapy showed a statistically significantly greater mean reduction in IPSS from baseline to 3-month follow-up than doxazosin (2.6 [95% CI 1.2 to 3.9], $p < 0.001$) and finasteride (5.2 [4.0 to 6.4], $p < 0.001$) but not compared with combination therapy (1.4 [0.0 to 2.8], $p = 0.05$). The results were sustained after 36 months: mean change of 1.8 [0.36 to 3.2], $p = 0.02$ for doxazosin compared with thermal therapy; 2.2 (1.0 to 3.4), $p < 0.001$ for finasteride compared with thermal therapy, and -0.27 (-1.9 to -1.4), $p = 0.73$ for combination compared with thermal therapy⁹.

In a retrospective case series of 129 patients with BPH, mean IPSS statistically significantly reduced from baseline to 91-to-180 day follow-up (% change \pm SD: -60.0 ± 28.7 , $p < 0.001$)¹⁰.

Benign prostatic hyperplasia impact index (BPHII)

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

In the RCT and case series of 197 patients, mean BPHII was statistically significantly lower in patients who had WVA (2.9 ± 2.9) compared with sham (4.7 ± 3.5 , $p=0.0003$) at 3-month follow-up. In the same study, patients crossing over to the WVA group had statistically significantly lower mean BPHII scores (2.6 ± 2.6) compared with the 3-month follow-up after sham (4.9 ± 3.5 , $p=0.024$) and this remained statistically significantly lower at 1-year follow-up (1.6 ± 2.3 , $p<0.0001$). In the same study, mean BPHII scores statistically significantly improved from baseline to 1-year follow-up (2.3 ± 3 , $p<0.0001$) in patients who had WVA, and this was maintained (2.4 ± 2.9 , $p<0.0001$) at 3-year follow-up¹⁻⁴.

In the case series of 65 patients who had WVA, mean BPHII scores statistically significantly improved from baseline to 1-month follow-up (5.5 ± 3.6 , $p=0.034$) and this was maintained at 2-year follow-up (2.3 ± 2.5 , $p<0.001$)⁶⁻⁸.

In the comparative study of 1,269 patients, thermal therapy showed a statistically significantly greater mean reduction in BPHII scores from baseline to 3-month follow-up than doxazosin (0.66 [0.13 to 1.2], $p=0.02$) and finasteride (0.64 [0.08 to 1.2], $p=0.03$) but not compared with the combination therapy (-0.12 [-0.71 to 0.48], $p=0.69$). After 36 months, the mean reduction in BPHII scores was statistically significantly greater for thermal therapy only when it was compared with doxazosin (1.2 [0.63 to 1.8], $p<0.001$)⁹.

Maximum urinary flow (Qmax)

In the RCT and case series of 197 patients, mean maximum urinary flow was statistically significantly higher in patients who had WVA (16.1 ± 7.3 mL/second) compared with sham (10.8 ± 4.0 mL/second, $p<0.0001$) at 3-month follow-up. In the same study, patients crossing over to the WVA group had statistically significantly higher maximum urinary flow (mean 16.4 ± 7.1 mL/second) compared with the previous 3-month follow-up after sham (10.4 ± 3.8 mL/second, $p<0.0001$), and maximum urinary flow was still statistically significantly increased from baseline assessment (mean 16.2 ± 7.9 , $p<0.0001$) at 1-year follow-up. In the same study, mean maximum urinary flow statistically significantly improved from baseline to 1-year follow-up in patients who had WVA (15.5 ± 6.7 , $p<0.0001$) and this increase was maintained (13.2 ± 4.8 , $p<0.0001$) at 3-year follow-up¹⁻⁴.

In the case series of 131 patients, mean maximum urinary flow statistically significantly increased from baseline to 3 to 6 month follow-up (11.6 ± 7.7 mL/second, $p=0.04$) but the improvement was not maintained at 12-month follow-up (10 ± 5 mL/second, $p=0.4$)⁵.

In the case series of 65 patients who had WVA, mean maximum urinary flow statistically significantly improved from baseline to 1-month follow-up (9.9 ± 3.9

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

mL/second, $p<0.001$) and this was maintained at 2-year follow-up (12 ± 6.2 , $p<0.001$)⁶⁻⁸.

In the comparative study of 1,269 patients, thermal therapy showed a statistically significantly greater increase in Qmax (ml/s) from baseline to 3-month follow-up than doxazosin (-1.5 [-2.8 to -2.0], $p=0.02$), finasteride (-3.6 [-5.1 to -2.1], $p<0.001$) and combination therapy (-3.5 [-4.6 to -2.3], $p<0.001$). After 36 months, the mean increase in Qmax was statistically significantly greater for thermal therapy only when it was compared with finasteride (-2.1 [-3.3 to -0.77], $p=0.002$)⁹.

In the retrospective case series of 129 patients, mean Qmax statistically significantly increased from baseline to 91-to-180 day follow-up (% change \pm SD: 72 ± 83 , $p<0.001$)¹⁰.

Post-void residual urine volume (PVR)

In the RCT and case series of 197 patients, mean PVR was not statistically significantly different in patients who had WVA (71.8 ± 72.2 mL) compared with sham (92.7 ± 77.8 mL, $p=0.108$) at 3-month follow-up. In the same study, mean PVR was not statistically significantly different from baseline values in patients crossing over to the WVA group (-17%, 83.8 ± 80.5 , $p=0.6$), at 1-year follow-up. In the same study, mean PVR values were statistically significantly reduced in patients who had WVA (55.1 ± 61.9 mL, $p=0.0004$) at 3-year follow-up¹⁻⁴.

In the case series of 131 patients, mean PVR statistically significantly reduced from baseline to 3 to 6 month follow-up (85.8 ± 167.3 mL, $p<0.0001$) and the improvement was maintained at 12-month follow-up (77.3 ± 122.1 mL, $p<0.0001$)⁵.

In the case series of 65 patients who had WVA, mean PVR statistically significantly improved from baseline to 1-month follow-up (67.1 ± 64.4 mL, $p=0.037$) but the difference was no longer statistically significant at 6-month follow-up (-25%, -21.4 ± 88.3 , $p=0.071$) or 2-year follow-up (62.8 ± 83.9 mL, $p=0.307$)⁶⁻⁸.

In the comparative study of 1,269 patients, thermal therapy showed a statistically significantly greater reduction in PVR (ml) from baseline to 3-month follow-up than doxazosin (-16.9 [-30.6 to -3.4], $p=0.02$). For finasteride and combination therapy, the reduction in PVR was similar to the mean reduction observed for thermal therapy. After 36 months, the mean reduction in PVR was similar for all the comparisons with thermal therapy⁹.

In the retrospective case series of 129 patients, mean PVR statistically significantly decreased from baseline to 91-to-180 day follow-up (% change: -32, $p=0.005$)¹⁰.

Quality of life

In the RCT and case series of 197 patients, quality of life (QOL) assessed by the IPSS-QOL question was statistically significantly better in patients who had WVA (mean 2.3 ± 1.5) compared with sham (mean 3.5 ± 1.5 , $p<0.0001$) at 3-month follow-up. In the same study, patients crossing over to the WVA group had statistically significantly better mean IPSS-QOL scores (1.9 ± 1.4) compared with the previous 3-month follow-up after sham (3.7 ± 1.5 , $p=0.0024$). In the RCT and case series of 197 men, mean IPSS-QOL scores were statistically significantly reduced from baseline to 1-year follow-up 1 in patients who had WVA (2.1 ± 1.5 , $p<0.0001$) and this reduction was maintained (2.1 ± 2.3 , $p<0.0001$) at 3-year follow-up¹⁻⁴.

In the case series of 131 patients, mean IPSS-QOL scores statistically significantly reduced from baseline to 3-month follow-up (2.3 ± 1.5 , $p<0.0001$) and the improvement was maintained at 1-year follow-up (2.5 ± 1.4 , $p<0.0001$)⁵.

In the case series of 65 patients who had WVA, mean IPSS-QOL scores statistically significantly improved from baseline to 1-month follow-up (2.9 ± 1.8 , $p<0.001$) and this was maintained at 2-year follow-up (1.8 ± 1.4 , $p<0.001$)⁶⁻⁸.

Overactive bladder (OAB) symptoms

In the RCT and case series of 197 patients, mean OAB symptom scores were statistically significantly better in patients who had WVA (24.9 ± 18) compared with sham (31.9 ± 20.7 , $p=0.022$) at 3-month follow-up. In the same study, mean OAB health related quality of life (HRQL) scores were statistically significantly better in patients who had WVA (82 ± 17.5) compared with sham (74.9 ± 19.3 , $p=0.001$) at 3-month follow-up. Similarly, men in the sham group crossing over to have WVA had a statistically significantly improved mean OAB-HRQL score (89.1 ± 12.6 , $p<0.00001$) and OAB symptom score (15.2 ± 12.4 , $p<0.00001$) at 1-year follow-up. In the same study, mean OAB-HRQL scores statistically significantly improved from baseline to year-1 follow-up in patients who had WVA (83.7 ± 18.2 , $p<0.0001$) and this increase was maintained (84.6 ± 15.4 , $p<0.0001$) at 3-year follow-up. Similarly, mean OAB symptom scores statistically significantly reduced from baseline to year-1 follow-up in patients who had WVA (20.6 ± 18.4 , $p<0.0001$) and this was maintained (21.6 ± 16.2 , $p<0.0001$) at 3-year follow-up¹⁻⁴.

Erectile function

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

In the RCT and case series of 197 patients, erectile function (EF) assessed using the erectile function-specific question of the international index of erectile function (IIEF-15) was not statistically significantly different in patients who had WVA (22.7 ± 8.4) compared with sham (mean 21.0 ± 9.1 , $p=0.795$) at 3-month follow-up. Overall, there was no statistically significantly difference in mean IIEF scores between patients who had WVA compared with sham at 3-month follow-up. In the same study, patients crossing over to the WVA group did not have statistically significantly better IIEF scores (mean 16.6 ± 11.3) compared with the previous 3-month follow-up after sham (17 ± 10.5 , $p=0.597$), but the improvement became statistically significant at 1-year follow-up (18.8 ± 10 , $p=0.018$). In the same study, minimal clinically important improvement in EF (defined as minimal IIEF-EF score increase of 2 points for men with mild erectile dysfunction, 5 for moderate erectile dysfunction and 7 for patients with severe erectile dysfunction) assessed by the IIEF questionnaires (EF question) were reported by 32 % (29/90) of sexually active men at 3-month follow-up and by 27% (21/77) of sexually active men at 12-month follow-up. The mean IIEF-EF question scores were not statistically significantly different from baseline values in patients who had WVA throughout follow-up of 3 years ($p=0.112$)¹⁻⁴.

In the case series of 131 patients, no sexual function data were collected using validated questionnaires but all patients were asked about sexual function. There was no de novo erectile or ejaculatory dysfunction⁵.

In the case series of 65 patients who had WVA, mean IIEF-15 scores were statistically significantly worse than baseline values at 1-month follow-up (10.3 ± 11.6 , $p=0.0019$) but the difference lost statistical significance at 3-month follow-up (14.5 ± 11.9 , $p=0.201$), 6 months (15.4 ± 12 , $p=0.102$) and 12 months (14.1 ± 11.8 , $p=0.210$). At 2-year follow-up, mean IIEF-15 score was statistically significantly improved from baseline (15.5 ± 11.5 , $p=0.006$)⁶⁻⁸.

Ejaculatory function

In the RCT and case series of 197 patients, there was no statistically significant difference in the male sexual health questionnaire for ejaculatory function scores (MSHQ-EjD) for men who had WVA (mean 9.7 ± 4.5) compared with sham (mean 9.6 ± 4.3 , $p=0.443$), or in MSHQ-EjQ bother scores in men who had WVA (mean 1.8 ± 1.7) compared with sham (mean 1.8 ± 1.8 , $p=0.623$) at 3-month follow-up. Similarly, at 3-month follow-up, MSHQ-EjD function (mean 8.9 ± 5.2 , $p=0.283$) and bother (mean 1.7 ± 1.7 , $p=0.678$) scores were not statistically significantly improved after WVA, compared with the 3-month follow-up after sham. Mean MSHQ-EjQ function scores (9.1 ± 4.6 , $p=0.484$) and mean MSHQ-EjQ bother scores (2.1 ± 1.9 , $p=0.297$) were also not statistically significantly improved in the IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

crossover group at 1-year follow-up. In the same study, mean MSHQ-EjD function scores statistically significantly reduced from baseline to 3-year follow-up in patients who had WVA (8.5 ± 4.5 , $p=0.003$). Mean MSHQ-EjD bother scores also statistically significantly reduced from preoperative values to 1-year follow-up (1.5 ± 1.5 , $p=0.0015$) and the reduction was maintained (1.6 ± 1.5 , $p=0.006$) at 3-year follow-up¹⁻⁴.

In the case series of 65 patients who had WVA, ejaculatory function assessed by IIEF-15 question-9 mean scores was not statistically significantly improved from baseline to 1-month follow-up (1.8 ± 2.3 , $p=0.151$) and at 2-year follow-up (2.7 ± 2.2 , $p=0.095$). Similarly, mean MSHQ-EjD function scores did not statistically significantly improve from baseline values at any point during follow-up. The MSHQ-EjD bother score did not statistically significantly improve for most of the follow-up period but had statistically significantly improved at the 2-year follow-up (0.8 ± 2.5 , $p=0.035$)⁶⁻⁸.

Incontinence

In the RCT and case series of 197 patients, the impact of incontinence on quality of life assessed by the short-form International Continence Society male incontinence score (ICSMIS-SF) statistically significantly reduced from baseline to 1-year follow-up in patients who had WVA (3 ± 2.8 , $p<0.0001$) and this was maintained (3 ± 2.6 , $p<0.0001$) at 3-year follow-up. In the same study, mean ICSMIS-SF scores statistically significantly reduced from baseline to 1-year follow-up in patients who crossed over to the WVA group (3.2 ± 2.6 , $p=0.018$) and this reduction (mean 2.6 ± 1.8 , $p<0.0001$) was maintained at 1-year follow-up¹⁻⁴.

Prostate volume

In the case series of 65 patients who had WVA, mean prostate volumes reduced by 14% (-8.5 cm^3) at 1-month follow-up, by 23% (-14.2 cm^3) at 3 months and by 29% (-17.7 cm^3) at 6-month follow-up, p value not reported⁶⁻⁸.

In the retrospective case series of 129 patients average prostate volumes (ml) decreased by 18%, from $49.9 (\pm 17.0 \text{ ml})$ before treatment to $41.0 (\pm 15.0 \text{ ml})$ by 6 months or more after treatment ($n=27$, $p<0.001$)¹⁰.

Reoperation

In the RCT and case series of 197 patients who had WVA, reoperation rate was 4% ($6/135$) at 3-year follow-up¹⁻⁴.

In the case series of 131 patients who had WVA, reoperation rate was 2% ($3/131$) at 12-month follow-up⁵.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

In the case series of 129 patients, additional BPH surgery was needed in 2% (3/129) of patients within 4 to 12-month follow-up¹⁰.

BPH medications

In the retrospective case series of 129 patients, of those who were taking an alpha-blocker and/or a 5-alpha reductase inhibitor preoperatively, 89% (85/95) of people were off all medications at their latest follow up¹⁰.

Patient satisfaction

In the retrospective case series of 129 patients, the mean procedural satisfaction was 4.2 out of a possible 5 (the survey response rate was 64% [83/129]). In total 59% of patients were very satisfied, 18% satisfied, 10% neutral, 8% dissatisfied, and 6% very dissatisfied with the procedure. The mean result satisfaction was 4 out of a possible 5. In total 40% of patients were very satisfied, 25% satisfied, 14% neutral, 4% dissatisfied, and 10% very dissatisfied with the result. In the same study, 86% of patients would recommend the procedure to a friend in similar circumstances¹⁰.

Safety summary

Damage to other tissue

Ablation outside the prostate happened in 1 patient in the case series of 65 patients. Follow-up at 1, 3 and 6 months showed complete resolution of the extraprostatic ablation without negative sequelae⁶⁻⁸.

Bleeding

Haematospermia was reported by 7% (10/136) and haematuria by 13% (17/136) of men in the RCT and case series of 197 patients¹⁻⁴.

Haematuria was reported by 14% (9/65) of patients in the case series of 65 patients⁶⁻⁸.

Infection

Suspected urinary tract infection was reported by 4% (5/136) of men, urinary tract infection (proven with culture) in 3% (4/136) and epididymitis in 3% (4/136) of men who had WVA in the RCT and case series of 197 patients¹⁻⁴.

Suspected urinary tract infections was reported by 20% (13/65) of patients and fever by 5% (3/65) of patients in the case series of 65 patients. Urethral secretion

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

(without haematuria or stones) was reported by 5% (5/65) of patients and terminal dribbling was reported by 3% (2/65) of patients in the same study⁸.

Urinary tract infection was reported in 17% (22/129) of patients and epididymo-orchitis in 2% (2/129) of patients after 4 to 12-month follow-up in the retrospective case series of 129 patients¹⁰.

Pain

Dysuria was reported by 17% (23/136) of patients and pelvic pain or discomfort by 3% (4/136) after WVA in the RCT and case series of 197 patients¹⁻⁴.

Pain or discomfort was reported by 11% (7/65) of patients and dysuria was reported by 22% (14/65) of patients in the case series of 65 patients. Scrotal pain or discomfort was reported by 3% (2/65) of patients in the same study⁶⁻⁸.

Urinary retention

De novo urinary retention was reported by 1 patient in the RCT and case series of 197 men¹⁻⁴. Acute urinary retention was reported by 4% (5/136) of men in the same study¹⁻⁴.

Acute urinary retention happened in 11% (14/131) of patients in the case series of 131 patients who had WVA⁵.

Urinary retention following catheter or stent removal was reported in 14% (18/129) of patients in the retrospective case series of 129 patients¹⁰.

Incontinence

Urinary incontinence was reported by 1 patient in the case series of 65 patients⁶⁻⁸.

Urinary incontinence was reported in 4% (5/129) of patients after 4 to 12-month follow-up in the case series of 129 patients¹⁰.

Other urinary problems

Urinary frequency was reported by 7% (9/136) of patients and urinary urgency by 6% (8/136) in the RCT and case series of 197 patients¹⁻⁴.

Urinary frequency, urgency, frequency and urgency, haematuria and nocturia were reported by less than 4% (5/131) of patients in the case series of 131 patients (frequencies not reported by adverse event)⁵.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Nocturia was reported by 8% (5/65), urinary urgency by 20% (13/65), urinary frequency by 6% (4/65) and poor stream by 14% (9/65) of patients in the case series of 65 patients⁶⁻⁸.

Postvoid dribbling was reported in 4% (5/129) of patients within 4 to 12-month follow-up in the case series of 129 patients¹⁰.

Vesical catheterisation/ urine drainage

Catheterisation after the procedure was needed in 90% (122/135) of patients for a mean of 3.4(± 3.2) days in the treatment group compared with 20% (12/61) of patients for a mean 0.9(± 0.8) days in the control group in the RCT and case series of 197 patients¹⁻⁴.

Catheterisation before discharge from hospital was needed in 55% (36/65) of patients because of precautionary catheter use (15 patients), inadequate voiding (14), haematuria (6), or dysuria (1), events that are often associated with rigid cystoscopy, in the case series of 65 patients. The median duration of catheter use was 4.1 days. An additional 11 patients (17%) needed catheterisation after discharge for a median of 3.8 days because of urinary retention or for travel convenience⁶⁻⁸.

Urine drainage after the procedure was reported in 100% (129/129) of men either with a catheter (65% [84/129] of patients for a mean 4.4 \pm 4.3 days) or with a stent (35% [45/129] of patients for a mean of 19.3 \pm 12.6 days) in the case series of 129 patients¹⁰.

Nausea and vomiting

Nausea or vomiting requiring hospitalisation was reported by 1 patient each in the RCT and case series of 197 men who had WVA¹⁻⁴.

Ejaculatory problems/ erectile dysfunction

Decreased ejaculatory volume was reported by 3% (4/136) of men and anejaculation by 3% (4/136) of men who had WVA in the RCT and case series of 197 patients¹⁻⁴.

Erectile dysfunction or retrograde ejaculation were reported in 3% (4/129) of patients within 4 to 12-month follow-up in the case series of 129 patients¹⁰.

Urethral stricture

Urethral stricture was reported in 2% (2/129) of patients within 4 to 12-month follow-up in the case series of 129 patients¹⁰.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Prostate tissue sloughing

Prostate tissue sloughing was reported in 4% (5/129) of patients within 4 to 12-month follow-up in the case series of 129 patients¹⁰.

Bladder stone

Bladder stone was reported in 1 patient within 4 to 12-month follow-up in the case series of 129 patients¹⁰.

Bladder neck contracture

Bladder neck contracture was reported in 1 patient within 4 to 12-month follow-up in the case series of 129 patients.¹⁰

Anecdotal and theoretical adverse events

In addition to safety outcomes reported in the literature, specialist advisers are asked about anecdotal adverse events (events which they have heard about) and about theoretical adverse events (events which they think might possibly occur, even if they have never happened). For this procedure, specialist advisers listed no anecdotal adverse events. They considered that the following were theoretical adverse events: urethral stricture, potential for thermal damage to the bladder urethra and rectum and difficulty in controlling bleeding.

The evidence assessed

Rapid review of literature

The medical literature was searched to identify studies and reviews relevant to transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. The following databases were searched, covering the period from their start to 26 April 2018: MEDLINE, PREMEDLINE, EMBASE, Cochrane Library and other databases. Trial registries and the Internet were also searched. No language restriction was applied to the searches (see the [literature search strategy](#)). Relevant published studies identified during consultation or resolution that are published after this date may also be considered for inclusion.

The following selection criteria (table 1) were applied to the abstracts identified by the literature search. Where selection criteria could not be determined from the abstracts the full paper was retrieved.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Table 1 Inclusion criteria for identification of relevant studies

| Characteristic | Criteria |
|-------------------|--|
| Publication type | Clinical studies were included. Emphasis was placed on identifying good quality studies. Abstracts were excluded where no clinical outcomes were reported, or where the paper was a review, editorial, or a laboratory or animal study. Conference abstracts were also excluded because of the difficulty of appraising study methodology, unless they reported specific adverse events that were not available in the published literature. |
| Patient | Patients with benign prostatic hyperplasia. |
| Intervention/test | Transurethral water vapour ablation. |
| Outcome | Articles were retrieved if the abstract contained information relevant to the safety and/or efficacy. |
| Language | Non-English-language articles were excluded unless they were thought to add substantively to the English-language evidence base. |

List of studies included in the IP overview

This IP overview is based on 497 patients from 1 randomised control study and case series¹⁻⁴, 1 comparative study⁹, and 3 case series^{5-8, 10}.

Other studies that were considered to be relevant to the procedure but were not included in the main extraction table (table 2) have been listed in the appendix.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Table 2 Summary of key efficacy and safety findings on transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Study 1, 2, 3 and 4 McVary KT (2016a, 2016b, 2017) and Roehrborn (2017)

Details

| | |
|--|---|
| Study type | RCT |
| Country | US |
| Recruitment period | 2013 to 2014 |
| Study population and number | n=197 (136 RFTT, 61 sham) men with BPH related moderate to severe LUTS. A total of 188 patients had RFTT in the randomised and crossover studies. |
| Age and sex | RFTT: 63±7.1 years, all males Sham: 62.9±7.0 years, all males |
| Patient selection criteria | <p><u>Inclusion criteria:</u> Men with moderate to severe symptomatic BPH, age>50 years, IPSS≥13, prostate volume of 30 to 80 cc, maximum urinary flow rate of ≤15 mL/s, PVR<250 ml,</p> <p><u>Exclusion criteria</u></p> <ul style="list-style-type: none"> • Prostate specific antigen level higher than 2.5 ng/mL with free prostate-specific antigen less than 25% (unless biopsy result was negative) • Active urinary tract infections or 2 separate infections within 6 months. <p>A more comprehensive list of exclusion criteria is available from https://clinicaltrials.gov/ct2/show/study/NCT01912339?sect=X4301256</p> <p>Men with median lobe were not excluded and could be treated at the discretion of the physician investigator.</p> |
| Technique | All subjects were washed out of α-blockers, anticholinergics, daily doses of phosphodiesterase-5 inhibitors (4 weeks), oestrogen, androgen-suppressing drugs, anabolic steroids, type II 5α-reductase inhibitors. Daily drug use of any medication for LUTS or ED was prohibited for the duration of the study. All patients had uroflowmetry and questionnaires applied after washout period and within 1 week of treatment. These were repeated at follow-up visits. Each 0.5ml radiofrequency water vapour injection is convectively delivered and dispersed circumferentially to create a 1.5 to 2 cm lesion and remains confined to the prostate zones. The control procedure closely replicated the experience of RFTT and the surgical barrier prevented subject visualisation of treating physician and device. All RFTT were done in office-based or ambulatory surgery settings, receiving only oral analgesia. |
| Follow-up | 3 years |
| Conflict of interest/source of funding | The authors declared that this was a study sponsored by NxThera Inc, manufacturer of the Rezūm device. NxThera were given the opportunity of reviewing the manuscript |

Analysis

Follow-up issues: Comparative outcomes for RFTT and control group were documented after 3-month follow-up when treatment assignment for all subjects was unblinded. Subjects in the treatment arm were re-evaluated at 6, 12, 24 and 36 months. Total expected follow-up is 5 years for the crossover subjects. Currently, data is available for the 3-year follow-up period.

A total of 72% (97/135) patients who had RFTT were available for the 3-year follow-up. Of the 38 patients excluded from the analysis, 14 were lost to follow-up, 7 withdrew consent (1 with a cancer diagnosis), 5 were censored for the use of BPH medications and 4 were censored for the use of testosterone at the time of follow-up, 2 missed a clinic visit and 6 had a secondary treatment for LUTS.

Study design issues: Prospective, multicentre (15 centres in the US), double-blinded RCT. Randomisation (2:1) was done with electronical programming before treatment using permuted blocks of random sizes. Treating physicians were not blinded. Double blinding was maintained until month 3 follow-up for patients and personnel administering the questionnaires. Qualified control subjects had the option to crossover to receive thermal therapy or no treatment. Of the 61 control subjects 87% (53/61) met IPSS and Qmax criteria and were elected for crossover active treatment.

Effectiveness of RFTT was assessed with the IPSS, quality of life, Qmax and BPH impact index; sexual function was evaluated with the IIEF-15 and MSHQ-EjD questionnaires. These were compared with controls at 3-month and to baseline at 1 to 3-year follow-up. The IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

primary end-point analysis per ITT in the RCT included all subjects at the 3-month evaluation including 2 men randomised to the treatment group who did not receive the treatment or initiate alternate therapy before 3 months. Subjects who reported no sexual intercourse were excluded from the analysis of sexual function.

Study population issues: Baseline characteristic were similar between comparators. Approximately 75% of treatment and control groups had severe LUTS (IPSS \geq 19), 25% had moderate LUTS (IPSS \leq 18). At baseline, in the RFTT group 52% of men had ED, 26% had absence of ejaculation and 32% were not sexually active. In the control group 54% had ED, 18% had absence of ejaculation and 33% were not sexually active (no statistically significant differences between groups).

About 52% in the treatment group and 54% in the controls had erectile dysfunction. The median lobe was identified in 37% (70/188) men and treated in 31% (58/188).

A mean of 4.7 ± 1.7 treatments was delivered to the prostate zones. A mean of 1.6 ± 0.7 treatments were delivered to the median prostate zone. Anaesthesia was varied from 69% of patients received oral sedation only, 21% received prostate block and 10% received intravenous sedation. Some subjects were electively catheterised for an average of 3.6 ± 3.5 days after treatment.

Other issues: This summary compiles 3 publications from the same RCT and crossover study. Sample size power calculations were not reported by the authors.

Key efficacy and safety findings

Efficacy

n=197 (136 RFTT, 61 sham)

Total of **135 men** who had RFTT (RCT and crossover combined)

Procedural pain VAS – 5.0 ± 2.7 RFTT, 4.9 ± 2.8 rigid cystoscope (controls)

Comparison of mean changes at 3 months between RFTT and control ITT groups

| Outcome Mean \pm SD | RFTT Mean \pm SD (n) | | | Sham Mean \pm SD (n) | | | P value |
|-------------------------------|---------------------------|--------------------------|------------------|---------------------------|-------------------------|----------------|---------|
| | Baseline | 3 months | Change | Baseline | 3 months | Change | |
| IPSS | 22 ± 4.8 (136) | 10.8 ± 6.5 (136) | -11.2 ± 7.6 | 21.9 ± 4.7 (61) | 17.5 ± 7.6 (61) | -4.3 ± 6.9 | <0.0001 |
| Qmax (mL/s) | 9.9 ± 2.3 (136) | 16.1 ± 7.3 (133) | 6.2 ± 7.1 | 10.4 ± 2.1 (61) | 10.8 ± 4.0 (61) | 0.5 ± 4.2 | <0.0001 |
| PVR (mL) | 82 ± 51.5 (136) | 71.8 ± 72.2 (133) | -10.6 ± 68.3 | 85.5 ± 51.6 (61) | 92.7 ± 77.8 (61) | 7.2 ± 77.4 | 0.108 |
| IPSS QoL | 4.4 ± 1.1 (136) | 2.3 ± 1.5 (134) | -2.1 ± 1.6 | 4.4 ± 1.1 (61) | 3.5 ± 1.5 (61) | -0.9 ± 1.5 | <0.0001 |
| BPHII | 6.3 ± 2.8 (136) | 2.9 ± 2.9 (134) | -3.4 ± 3.5 | 6.2 ± 2.9 (61) | 4.7 ± 3.5 (61) | -1.5 ± 3.0 | 0.0003 |
| OAB Bother scale | 39.6 ± 18 (136) | 24.9 ± 18 (133) | -14.6 ± 18.4 | 39.9 ± 20.7 (61) | 31.9 ± 20.7 (61) | -8 ± 17.9 | 0.022 |
| OAB HRQL | 64.5 ± 20 (136) | 82 ± 17.5 (132) | 17.5 ± 18.8 | 66.7 ± 16.9 (61) | 74.9 ± 19.3 (60) | 8.3 ± 15.7 | 0.001 |
| IIEF erectile function domain | 22.6 ± 7.4 (91) | 22.7 ± 8.4 (90) | 0.1 ± 7.4 | 21.2 ± 8.3 (40) | 21.0 ± 9.1 (40) | -0.3 ± 5.6 | 0.795 |
| MSHQ-EjD function | 9.3 ± 3.1 (91) | 9.7 ± 4.5 (90) | 0.3 ± 4.3 | 9.8 ± 3.6 (40) | 9.6 ± 4.3 (40) | -0.2 ± 3.2 | 0.443 |
| MSHQ-EjD bother | 2.2 ± 1.7 (91) | 1.8 ± 1.7 (90) | -0.4 ± 1.9 | 2 ± 1.7 (40) | 1.8 ± 1.8 (40) | -0.2 ± 1.9 | 0.623 |

Erectile function (3 months)

There was no statistically significantly difference in mean scores between patients who had RFTT and controls for any of IIEF-15 domains at the 3-month follow-up.

MCID of change in IIEF erectile function domain score at 3 and 12 months after RFTT

| | Month 3 (n=90 sexually active) | | Month 12 (n=77 sexually active) | |
|----------------------------------|--------------------------------|-------------------|---------------------------------|-------------------|
| | n/N | MCID ² | n/N | MCID ² |
| IIEF-EF baseline severity | | | | |
| Severe (1 to 10) | 2/7 | 12.5 ± 4.9 | 2/3 | 11.5 ± 3.5 |
| Moderate (11 to 16) | 5/15 | 10.1 ± 4.6 | 6/13 | 11.2 ± 4.4 |
| Mild (17 to 25) | 18/68 | 4 ± 2.2 | 13/61 | 5.3 ± 2.8 |
| Improved scores | 32 % (29/90) | | 27% (21/77) | |

Reoperation

Reoperation rate was 4% (6/135) at 3 years follow-up.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Mean outcome measures at 3 months during control/sham and crossover periods

| | Sham Mean±SD (n) | | | Crossover to RFTT Mean±SD (n) | | | P value |
|--------------------------|---------------------|------------------|----------|----------------------------------|--------------------|----------|---------|
| | Baseline | 3 months | Change | Baseline | 3 months | Change | |
| IPSS | 21.9±4.9 (50) | 18±7.6 (50) | -3.9±6.7 | 19.1±6.7 (50) | 9.8±6 (50) | -10±7.1 | 0.0004 |
| Qmax (mL/s) | 10.2±2.2 (49) | 10.4±3.8 (49) | 0.2±3.9 | 10.1±3.7 (49) | 16.4±7.1 (49) | 6.3±6.8 | <0.0001 |
| IPSS QoL | 4.5±1.1 (50) | 3.7±1.5 (50) | -0.8±1.5 | 3.9±1.4 (50) | 1.9±1.4 (50) | -2±1.8 | 0.0024 |
| BPHII | 6.2±2.8 (50) | 4.9±3.5 (50) | -1.3±2.9 | 5.5±3.2 (50) | 2.6±2.6 (50) | -2.9±3.3 | 0.024 |
| IIEF-15 | 16.1±10 (47) | 17±10.5 (47) | 0.9±6.1 | 16.7±10.4 (47) | 16.6±11. 3 (47) | -0.1±8.9 | 0.597 |
| MSHQ-EjD Function | 9.1±4 (46) | 9.4±4.4 (47) | 0.6±3.0 | 9.5±4.2 (46) | 8.9±5.2 (47) | -0.4±4 | 0.283 |
| MSHQ-EjD bother | 2.0±1.8 (46) | 1.7±1.8 (47) | -0.3±1.7 | 1.8±1.8 (46) | 1.7±1.7 (47) | -0.1±1.9 | 0.678 |

Mean outcome measures in crossover subjects after RFTT

| Outcome | 3 months | p | 6 months | p | 12 months | p |
|------------------------------|-----------|----------|-----------|----------|-----------|------------------|
| IPSS (n) | 50 | | 49 | | 45 | |
| Baseline | 19.9±6.7 | p<0.0001 | 20.1±6.7 | p<0.0001 | 19.4±66. | p<0.0001 |
| Follow-up | 9.8±6 | | 10.2±6.9 | | 8.6±6.6 | |
| IPSS QoL (n) | 50 | | 49 | | 45 | |
| Baseline | 3.9±1.4 | p<0.0001 | 3.9±1.4 | p<0.0001 | 3.8±1.3 | p<0.0001 |
| Follow-up | 1.9±1.4 | | 2±1.4 | | 1.7±1.2 | |
| Qmax (mL/s) (n) | 49 | | 49 | | 45 | |
| Baseline | 10.1±3.7 | p<0.000 | 10.1±3.7 | p<0.0001 | 10.3±3.8 | p<0.0001 |
| Follow-up | 16.4±7.1 | | 16.1±7.2 | | 16.2±7.9 | |
| PVR volume (mL) (n) | 49 | | 49 | | 44 | |
| Baseline | 95.8±79.2 | p=0.096 | 91.6±75.6 | -p=0.06 | 101±79.2 | p=0.6 |
| Follow-up | 67.3±64.2 | | 67.3±64.9 | | 83.8±80.5 | |
| BPHII (n) | 50 | | 49 | | 45 | |
| Baseline | 5.5±3.2 | p<0.0001 | 5.6±3.3 | p<0.0001 | 5.3±3.2 | p<0.0001 |
| Follow-up | 2.6±2.6 | | 2.3±2.5 | | 1.6±2.3 | |
| IIEF-15 (n) | 29 | | 28 | | 26 | |
| Baseline | 23.2±6.8 | p=0.331 | 21.8±7.5 | p<0.358 | 22.8±6.6 | -18%, p=0.018 |
| Follow-up | 21.3±10.3 | | 20.9±9.2 | | 18.8±10 | |
| MSHQ-EjD function (n) | 30 | | 28 | | 26 | |
| Baseline | 9.9±3.8 | p=0.603 | 9.8±3.9 | p=0.177 | 9.8±3.6 | p=0.484 |
| Follow-up | 9.7±5.1 | | 8.6±4.9 | | 9.1±4.6 | |
| MSHQ-EjD bother (n) | 30 | | 30 | | 26 | |
| Baseline | 1.6±1.7 | p=0.681 | 1.8±1.8 | p=0.683 | 1.7±1.7 | p=0.297 |
| Follow-up | 1.6±1.6 | | 1.8±1.7 | | 2.1±1.9 | |
| ICSMIS-SF (n) | 50 | | 49 | | 45 | |
| Baseline | 4.3±3 | p=0.018 | 4.4±3 | p=0.0023 | 3.9±2.5 | p<0.0001 |
| Follow-up | 3.2±2.6 | | 3.3±2.7 | | 2.6±1.8 | |
| OAB HRQL Score (n) | 49 | | 48 | | 45 | |
| Baseline | 72.5±18.9 | p<0.0001 | 72.2±19.2 | p<0.0001 | 75.2±17.6 | p<0.00001 |
| Follow-up | 86.7±15.2 | | 86.2±16 | | 89.1±12.6 | |

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

| OAB Symptom score (n) | 50 | | 49 | | 45 | |
|-----------------------|-----------|----------|-----------|----------|-----------|-----------|
| Baseline | 33.1±19 | p<0.0001 | 33.4±20.9 | p<0.0001 | 30.1±17.9 | |
| Follow-up | 21.4±18.3 | | 20±18.7 | | 15.2±12.4 | p<0.00001 |

Mean outcome changes after convective RFTT from baseline through 3 years (treatment group)

| Outcome | 1 year | p | 2 years | p | 3 years | p |
|------------------------------|------------|----------|------------|----------|-----------|----------|
| IPSS (n) | 121 | | 109 | | 97 | |
| Baseline | 21.8±4.8 | | 21.4±4.5 | | 21.4±4.6 | |
| Follow-up | 10.3±6.7 | p<0.0001 | 10.2±6.2 | <0.0001 | 10.4±6.1 | p<0.0001 |
| IPSS QoL (n) | 121 | | 109 | | 97 | |
| Baseline | 4.4±1.1 | | 4.3±1.0 | | 4.3±1.0 | |
| Follow-up | 2.1±1.5 | p<0.0001 | 2.1±1.4 | p<0.0001 | 2.1±1.3 | p<0.0001 |
| Qmax (mL/s) (n) | 112 | | 99 | | 80 | |
| Baseline | 10±2.2 | | 10±2.2 | | 9.7±2.0 | |
| Follow-up | 15.5±6.7 | p<0.0001 | 14.7±6.1 | p<0.0001 | 13.2±4.8 | p<0.0001 |
| PVR volume (mL) (n) | 118 | | 106 | | 92 | |
| Baseline | 82.5±51.2 | | 84.9±54 | | 81.5±2.0 | |
| Follow-up | 78.6±79.9 | p=0.894 | 84.6±92 | p=0.654 | 55.1±61.9 | p=0.0004 |
| BPHII (n) | 121 | | 109 | | 97 | |
| Baseline | 6.2±2.8 | | 6.1±2.8 | | 6.1±2.9 | -61%, |
| Follow-up | 2.3±3 | p<0.0001 | 2.3±2.7 | p<0.0001 | 2.4±2.9 | p<0.0001 |
| IIEF-15 (n) | 77 | | 71 | | 62 | |
| Baseline | 23.3±6.9 | | 22.9±7.3 | | 23.2±7.4 | |
| Follow-up | 23±8.4 | p=0.871 | 21.8±8.7 | p=0.408 | 21.3±9.1 | p=0.112 |
| MSHQ-EjD function (n) | 78 | | 70 | | 63 | |
| Baseline | 9.6±3 | | 9.6±3 | | 9.9±3 | |
| Follow-up | 9.3±4 | p=0.278 | 9.1±4.4 | p=0.351 | 8.5±4.5 | p=0.003 |
| MSHQ-EjD bother (n) | 79 | | 70 | | 63 | |
| Baseline | 2.2±1.6 | | 2.2±1.6 | | 2±1.6 | |
| Follow-up | 1.5±1.5 | p=0.0015 | 1.7±1.7 | p=0.0129 | 1.6±1.5 | p=0.006 |
| ICSMIS-SF (n) | 120 | | 109 | | 97 | |
| Baseline | 4.3±2.8 | | 4.2±2.4 | | 4.1±2.3 | |
| Follow-up | 3±2.8 | p<0.0001 | 3±2.6 | p<0.0001 | 3±2.6 | p<0.0001 |
| OAB HRQL Score (n) | 120 | | 106 | | 95 | |
| Baseline | 65.8±18.9 | | 66.6±18.3 | | 66.7±18.2 | |
| Follow-up | 83.7±18.2 | p<0.0001 | 85.6±15.1 | p<0.0001 | 84.6±15.4 | p<0.0001 |
| OAB Symptom score (n) | 121 | | 109 | | 97 | |
| Baseline | 39±17.5 | | 38.2±17.2 | | 37.5±16.2 | |
| Follow-up | 20.6±18.4 | p<0.0001 | 20.9±16.6 | p<0.0001 | 21.6±16.2 | p<0.0001 |
| PSA (ng/mL) (n) | 120 | | 109 | | 96 | |
| Baseline | 2.1±1.6 | | 2.1±1.6 | | 2±1.6 | |
| Follow-up | 1.8±1.3 | p=0.0003 | 1.8±1.6 | p=0.0015 | 1.8±1.7 | p=0.0947 |

Safety

| Related serious adverse events | RFTT | Controls |
|---|--------------|-----------|
| Nausea ³ | 1/136 | 0/61 |
| Vomiting ³ | 1/136 | 0/61 |
| De-novo urinary retention | 1/136 | 0/61 |
| Non-serious adverse events⁴ | | |
| Dysuria | 17% (23/136) | 2% (1/61) |

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

| | | |
|---|--------------|-----------|
| Haematuria | 13% (17/136) | 0/61 |
| Urinary frequency | 7% (9/136) | 3% (2/61) |
| Urinary urgency | 6% (8/136) | 2% (2/61) |
| Acute urinary retention | 4% (5/136) | 0/61 |
| Suspected urinary tract infection | 4% (5/136) | 0/61 |
| Urinary tract infection (proven with culture) | 3% (4/136) | 0/61 |
| Haematospermia | 7% (10/136) | 0/61 |
| Decreased ejaculatory volume | 3% (4/136) | 0/61 |
| Anejaculation | 3% (4/136) | 0/61 |
| Epididymitis | 3% (4/136) | 2% (1/61) |
| Pelvic pain of discomfort | 3% (4/136) | 0/61 |

¹Voided volume ≥ 125 mL

²MCID is a minimal IIEF-EF score increase of 2 for men with mild erectile dysfunction, an increase of 5 for moderate erectile dysfunction, and 7 for severe erectile dysfunction.

³Requiring hospitalisation overnight for observation

⁴Data extracted from original papers and authors report available from
<https://clinicaltrials.gov/ct2/show/results/NCT01912339?sect=X4301256#othr>

Post-operative catheterisation rate

- Treatment group: 90% (122/135) of patients were catheterised for a mean of 3.4 ± 3.2 days
 Of these, 68% (83 of 122) were discretionary and 32% (39 of 122) were due to an unsuccessful voiding trial before discharge.
- Control group: 20% (12/61) of patients were catheterised for a mean 0.9 ± 0.8 days

Abbreviations used: BPH, benign prostatic hyperplasia; ED, erectile dysfunction; ICSMI-SF, international continence society male incontinence score - short form; IIEF-15, international index of erectile function; IPSS, international prostate symptom score; ITT, intention to treat; LUTS, lower urinary tract symptoms; HRQL, health related quality of life; MCID, minimal clinical important differences; MSHQ-EjD, male sexual health questionnaire for ejaculatory function; ng, nanogram; OAB, overactive bladder; PSA, prostate specific antigen; PVR, post-void residual urine volume; Qmax, peak urinary flow; QoL, quality of life; RCT, randomised control trial; SD, standard deviation; VAS, visual analogue scale; RFTT, convective radiofrequency thermal treatment.

Study 5 Darson MF (2017)

Details

| | |
|--|--|
| Study type | Case series |
| Country | US |
| Recruitment period | 2015 to 2017 |
| Study population and number | n=131 patients with moderate to severe LUTS due to BPH who had RFTT in 2 group practices |
| Age and sex | Mean 70.9 (47 to 96) years, males |
| Patient selection criteria | Consecutive patients with moderate to severe LUTS were offered RFTT as an alternative to medications for symptomatic relief of BPH, after inadequate relief or drug intolerance. Urologists used their own discretion for patient selection with variable prostate sizes, LUTS severity, urinary retention or presence of an obstructing median lobe. Patient selection and treatment did not follow a standardised protocol. |
| Technique | Analgesia consisted of intravenous sedation (86% [113/131]), general anaesthesia (15% [20/131]) or prostate block (6% [8/131]) followed by posttreatment analgesics. |
| Follow-up | 12 months |
| Conflict of interest/source of funding | The authors declared having consulted for NxThera, manufacturer of the Rezūm device. |

Analysis

Follow-up issues: Although the intention was to follow-up as many patients as possible, there was no obligation for patients to comply with follow-up evaluations. Patients were offered follow-up visits at 1, 3, 6 and 12 months.

Study design issues: Pre and post procedure assessments included IPSS, QoL, peak urinary flow rate, voided volume and PVR. The results were reported separately according to LUTS severity: IPSS 8 to 19 and IPSS 20 to 35. Safety events and surgical retreatment rates were monitored prospectively.

The clinically meaningful threshold for improvement was defined as a greater or equal than 3-point increase in IPSS relative to baseline, as suggested by the American Urological Association.

Study population issues: Preoperative mean prostatic volume was 45.1 (range 12.9 to 183) cm³ and mean PVR was 216 (range 0 to 2,000) ml with 26% (34/131) of patients having a PVR volume \geq 250 ml. There were 12% of patient having previous surgery or minimally invasive surgical procedures, including TURP (2% [3/131]), transurethral conductive radiofrequency thermal therapy (7% [9/131]), transurethral microwave thermal therapy (1/131), transurethral microwave thermal therapy and prostatic urethral lift (1/131) and Rezūm RFTT (2% [2/131]). The average preoperative LUTS severity was moderate (IPSS 8 to 19) in 53% (68/131) of patients and severe (IPSS 20 to 35) in 47% (60/131).

The total number of treatments in lateral lobes averaged 4.4 (range 2 to 12). The median lobe or enlarged central zone was identified and treated in 41% (54/131) of patients with an average of 1.6 (range 1 to 6) treatments.

Other issues: None.

Key efficacy and safety findings

| Efficacy | | | | | Safety | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|-----------------|---------------------------------|-------------|--------------|---------|---------------|--|---------|--|---------|--|---------|--|--|------------|-----------|--|-----------|--|-----------|-------------|--|--|--|--|--|--|-------------------|-----|----|----|----|--|--|----------|----------|----------|--------|----------|--|--|-----------|---------|----------|---------|--------|--|--|--------|-----------|----------|----------|-----------|--|--|---------|---------|---------|---------|---------|--|--|-----------------|--|--|--|--|--|--|-------------------|-----|----|----|----|--|--|----------|---------|---------|---------|---------|--|--|-----------|---------|---------|---------|---------|--|--|--------|--------|----------|----------|----------|--|--|---------|---------|---------|---------|---------|--|--|--------------------|--|--|--|--|--|--|-------------------|----|---|---|---|--|--|----------|---------|-----------|---------|---------|--|--|-----------|----------|------|---------|----------|--|--|--------|-----|---------|---------|---------|--|--|---------|------|-----|------|------|--|--|-----------------|--|--|--|--|--|--|-------------------|----|----|----|----|--|--|----------|-------------|-------------|-------------|-------------|--|--|-----------|------------|------------|------------|---------|--|--|--------|------------|------------|------------|------------|--|--|---------|---------|---------|---------|---------|--|--|---------------------------|--|--|--|--|--|--|-------------------|----|---|---|---|--|--|----------|-------------|-------------|-------------|-------------|--|--|-----------|-------------|-------------|-----------|------------|--|--|--------|-------------|-------------|------------|----------|--|--|---------|------|------|------|------|--|--|--|--|--|--|--|--|--|--|--|--|--|--|---|--|--|--|--|--|
| n=131 Changes in outcome measures after RFTT by LUTS severity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th rowspan="2">Outcome measure</th> <th colspan="2">IPSS 8 to 35 (all participants)</th> <th colspan="2">IPSS 8 to 19</th> <th colspan="2">IPSS 20 to 35</th> </tr> <tr> <th colspan="2">Mean±SD</th> <th colspan="2">Mean±SD</th> <th colspan="2">Mean±SD</th> </tr> <tr> <th></th> <th>3-6 months</th> <th>12 months</th> <th></th> <th>12 months</th> <th></th> <th>12 months</th> </tr> </thead> <tbody> <tr> <td>IPSS</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>n (paired values)</td><td>115</td><td>87</td><td>46</td><td>41</td><td></td><td></td></tr> <tr> <td>Baseline</td><td>19.9±6.7</td><td>19.4±6.7</td><td>14.1±3</td><td>25.4±4.1</td><td></td><td></td></tr> <tr> <td>Follow-up</td><td>9.8±6.9</td><td>10.1±7.2</td><td>8.3±6.6</td><td>12±7.3</td><td></td><td></td></tr> <tr> <td>Change</td><td>-10.1±8.8</td><td>-9.4±8.7</td><td>-5.8±6.5</td><td>-13.4±9.2</td><td></td><td></td></tr> <tr> <td>P value</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td></td><td></td></tr> <tr> <td>IPSS QOL</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>n (paired values)</td><td>104</td><td>74</td><td>39</td><td>34</td><td></td><td></td></tr> <tr> <td>Baseline</td><td>4.3±1.2</td><td>4.4±1.3</td><td>3.8±1.4</td><td>4.9±0.9</td><td></td><td></td></tr> <tr> <td>Follow-up</td><td>2.3±1.5</td><td>2.5±1.4</td><td>2.3±1.5</td><td>2.6±1.3</td><td></td><td></td></tr> <tr> <td>Change</td><td>-2±1.7</td><td>-1.9±1.8</td><td>-1.5±1.9</td><td>-2.3±1.6</td><td></td><td></td></tr> <tr> <td>P value</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td></td><td></td></tr> <tr> <td>Qmax (ml/s)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>n (paired values)</td><td>38</td><td>7</td><td>3</td><td>4</td><td></td><td></td></tr> <tr> <td>Baseline</td><td>8.7±4.7</td><td>8.5 (3.5)</td><td>8.1±4.6</td><td>8.8±3.2</td><td></td><td></td></tr> <tr> <td>Follow-up</td><td>11.6±7.7</td><td>10±5</td><td>9.3±3.2</td><td>10.5±6.5</td><td></td><td></td></tr> <tr> <td>Change</td><td>3±9</td><td>1.5±5.9</td><td>1.2±7.6</td><td>1.7±5.5</td><td></td><td></td></tr> <tr> <td>P value</td><td>0.04</td><td>0.4</td><td>0.57</td><td>0.82</td><td></td><td></td></tr> <tr> <td>PVR (ml)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>n (paired values)</td><td>89</td><td>35</td><td>17</td><td>18</td><td></td><td></td></tr> <tr> <td>Baseline</td><td>243.8±316.7</td><td>236.6±341.3</td><td>281.6±461.6</td><td>194.1±168.8</td><td></td><td></td></tr> <tr> <td>Follow-up</td><td>85.8±167.3</td><td>77.3±122.1</td><td>96.6±166.4</td><td>59±55.2</td><td></td><td></td></tr> <tr> <td>Change</td><td>-158±221.8</td><td>-159±254.7</td><td>-185±340.5</td><td>-135±138.9</td><td></td><td></td></tr> <tr> <td>P value</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td><0.0001</td><td></td><td></td></tr> <tr> <td>Voided volume (ml)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>n (paired values)</td><td>38</td><td>7</td><td>3</td><td>4</td><td></td><td></td></tr> <tr> <td>Baseline</td><td>192.3±119.4</td><td>182.7±119.4</td><td>223.7±124.1</td><td>151.9±123.7</td><td></td><td></td></tr> <tr> <td>Follow-up</td><td>146.7±100.6</td><td>138.4±103.1</td><td>120±129.2</td><td>152.3±97.7</td><td></td><td></td></tr> <tr> <td>Change</td><td>-45.5±149.8</td><td>-44.2±146.6</td><td>-104±230.2</td><td>0.3±38.4</td><td></td><td></td></tr> <tr> <td>P value</td><td>0.19</td><td>0.51</td><td>0.36</td><td>0.79</td><td></td><td></td></tr> <tr> <td colspan="6"><u>Erectile and ejaculatory function</u></td></tr> <tr> <td colspan="6">The study did not collect sexual function data via a validated questionnaire but all patients were asked about sexual function and there was no de novo erectile or ejaculatory dysfunction.</td></tr> <tr> <td colspan="6"><u>Reoperation rate at 12 month follow-up:</u> 2% (3/131)</td></tr> </tbody> </table> | Outcome measure | IPSS 8 to 35 (all participants) | | IPSS 8 to 19 | | IPSS 20 to 35 | | Mean±SD | | Mean±SD | | Mean±SD | | | 3-6 months | 12 months | | 12 months | | 12 months | IPSS | | | | | | | n (paired values) | 115 | 87 | 46 | 41 | | | Baseline | 19.9±6.7 | 19.4±6.7 | 14.1±3 | 25.4±4.1 | | | Follow-up | 9.8±6.9 | 10.1±7.2 | 8.3±6.6 | 12±7.3 | | | Change | -10.1±8.8 | -9.4±8.7 | -5.8±6.5 | -13.4±9.2 | | | P value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | | | IPSS QOL | | | | | | | n (paired values) | 104 | 74 | 39 | 34 | | | Baseline | 4.3±1.2 | 4.4±1.3 | 3.8±1.4 | 4.9±0.9 | | | Follow-up | 2.3±1.5 | 2.5±1.4 | 2.3±1.5 | 2.6±1.3 | | | Change | -2±1.7 | -1.9±1.8 | -1.5±1.9 | -2.3±1.6 | | | P value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | | | Qmax (ml/s) | | | | | | | n (paired values) | 38 | 7 | 3 | 4 | | | Baseline | 8.7±4.7 | 8.5 (3.5) | 8.1±4.6 | 8.8±3.2 | | | Follow-up | 11.6±7.7 | 10±5 | 9.3±3.2 | 10.5±6.5 | | | Change | 3±9 | 1.5±5.9 | 1.2±7.6 | 1.7±5.5 | | | P value | 0.04 | 0.4 | 0.57 | 0.82 | | | PVR (ml) | | | | | | | n (paired values) | 89 | 35 | 17 | 18 | | | Baseline | 243.8±316.7 | 236.6±341.3 | 281.6±461.6 | 194.1±168.8 | | | Follow-up | 85.8±167.3 | 77.3±122.1 | 96.6±166.4 | 59±55.2 | | | Change | -158±221.8 | -159±254.7 | -185±340.5 | -135±138.9 | | | P value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | | | Voided volume (ml) | | | | | | | n (paired values) | 38 | 7 | 3 | 4 | | | Baseline | 192.3±119.4 | 182.7±119.4 | 223.7±124.1 | 151.9±123.7 | | | Follow-up | 146.7±100.6 | 138.4±103.1 | 120±129.2 | 152.3±97.7 | | | Change | -45.5±149.8 | -44.2±146.6 | -104±230.2 | 0.3±38.4 | | | P value | 0.19 | 0.51 | 0.36 | 0.79 | | | <u>Erectile and ejaculatory function</u> | | | | | | The study did not collect sexual function data via a validated questionnaire but all patients were asked about sexual function and there was no de novo erectile or ejaculatory dysfunction. | | | | | | <u>Reoperation rate at 12 month follow-up:</u> 2% (3/131) | | | | | |
| Outcome measure | | IPSS 8 to 35 (all participants) | | IPSS 8 to 19 | | IPSS 20 to 35 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Mean±SD | | Mean±SD | | Mean±SD | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 3-6 months | 12 months | | 12 months | | 12 months | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IPSS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| n (paired values) | 115 | 87 | 46 | 41 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline | 19.9±6.7 | 19.4±6.7 | 14.1±3 | 25.4±4.1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Follow-up | 9.8±6.9 | 10.1±7.2 | 8.3±6.6 | 12±7.3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change | -10.1±8.8 | -9.4±8.7 | -5.8±6.5 | -13.4±9.2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| P value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IPSS QOL | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| n (paired values) | 104 | 74 | 39 | 34 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline | 4.3±1.2 | 4.4±1.3 | 3.8±1.4 | 4.9±0.9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Follow-up | 2.3±1.5 | 2.5±1.4 | 2.3±1.5 | 2.6±1.3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change | -2±1.7 | -1.9±1.8 | -1.5±1.9 | -2.3±1.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| P value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Qmax (ml/s) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| n (paired values) | 38 | 7 | 3 | 4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline | 8.7±4.7 | 8.5 (3.5) | 8.1±4.6 | 8.8±3.2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Follow-up | 11.6±7.7 | 10±5 | 9.3±3.2 | 10.5±6.5 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change | 3±9 | 1.5±5.9 | 1.2±7.6 | 1.7±5.5 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| P value | 0.04 | 0.4 | 0.57 | 0.82 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PVR (ml) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| n (paired values) | 89 | 35 | 17 | 18 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline | 243.8±316.7 | 236.6±341.3 | 281.6±461.6 | 194.1±168.8 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Follow-up | 85.8±167.3 | 77.3±122.1 | 96.6±166.4 | 59±55.2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change | -158±221.8 | -159±254.7 | -185±340.5 | -135±138.9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| P value | <0.0001 | <0.0001 | <0.0001 | <0.0001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Voided volume (ml) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| n (paired values) | 38 | 7 | 3 | 4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Baseline | 192.3±119.4 | 182.7±119.4 | 223.7±124.1 | 151.9±123.7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Follow-up | 146.7±100.6 | 138.4±103.1 | 120±129.2 | 152.3±97.7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change | -45.5±149.8 | -44.2±146.6 | -104±230.2 | 0.3±38.4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| P value | 0.19 | 0.51 | 0.36 | 0.79 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <u>Erectile and ejaculatory function</u> | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| The study did not collect sexual function data via a validated questionnaire but all patients were asked about sexual function and there was no de novo erectile or ejaculatory dysfunction. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <u>Reoperation rate at 12 month follow-up:</u> 2% (3/131) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| © NICE 2018. All rights reserved. Subject to Notice of rights | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

¹Frequencies not reported by type of adverse event.

There were no statistically significantly difference in MCID IPSS between the two centres doing the procedure.

Abbreviations used: BPH, benign prostatic hyperplasia; IPSS, international prostate symptom score; LUTS, lower urinary tract symptoms; MCID, minimal clinical important differences; PVR, post-void residual urine volume; Qmax, peak urinary flow; QoL, quality of life; SD, standard deviation; VAS, visual analogue scale; RFTT, convective radiofrequency thermal treatment.

Study 6, 7 and 8 Dixon CM (2015 & 2016) & Mynderse LA (2015)

Details

| | |
|--|--|
| Study type | Case series |
| Country | Czech Republic, Dominican Republic, Sweden |
| Recruitment period | |
| Study population and number | n=65 men with moderate to severe LUTS secondary to BPH who had RFTT using the Rezum device |
| Age and sex | 66.6 (range 50 to 90) years, males |
| Patient selection criteria | <p><u>Inclusion criteria:</u> Age \geq 45 years, IPSS \geq 13, Qmax \leq 15 ml/s and prostate volume 20 to 120 cm³, voided volume \geq 125 ml and PVR $<$ 300ml.</p> <p><u>Exclusion criteria:</u> Confirmed or suspected prostate or bladder cancer, active urinary tract infection or bacterial prostatitis within the last year. Men taking concomitant drug therapy for LUTS.</p> <p>Individuals with a median lobe were not excluded and could be treated at the physician investigator' discretion.</p> |
| Technique | <p>Patients had a washout period from antihistamines, antispasmodics (1 week, except if documented evidence of stable dosing for the last 6 months), α-blockers, androgens, gonadotropin-releasing hormone analogues (2 weeks), 5α-reductase inhibitors (6 months), and from the use of antidepressants, anticholinergics, anticonvulsants, β-blockers (unless with documented evidence of stable dosing).</p> <p>Of the 65 patients 79% (51/65) received oral sedation and 21% (14/65) had intravenous sedation.</p> <p>Initial thermal treatment procedures in this pilot study evolved with slight modifications to optimise the water vapour delivery and endoscopic technique. These modifications in dosimetry and technique were guided by serial gadolinium-enhanced MRI to monitor the size and location of ablative lesions, their time course of resolution and the corresponding change in prostate tissue volume. MRI results were available in 59 of 65 patients.</p> |
| Follow-up | 2 years |
| Conflict of interest/source of funding | The authors declared being clinical trial investigators for NxThera and some authors declared being consultants for NxThera. Some authors and the Mayo clinic declared having financial interest in the Analyse 11.0 image and analysis technology used in this research. This study was funded by MxThera, manufacturer of the Rezum device. |

Analysis

Follow-up issues: Post-procedure follow-up happened at 1 week, 1, 3, 6, 12 and 24 months. Eighty-nine percent (58-65) of men completed the 1-year follow-up and 66% (43-65) the 2-year follow-up. In the first 212 months there were 7 patients not completing the study: 3 were lost to follow-up, 2 were relocated and 2 had poor health (1 de novo diagnose of prostate cancer). In the 12 to 24-month follow-up 2 patients died, 2 had other treatments (TURP, open prostatectomy), 4 were lost to follow-up or had a second phase of treatment with RFTT (5 men).

Study design issues: Self-administered questionnaires were completed at follow-up including IPSS, QoL instruments (IPSS QoL, BPHII), and sexual function with the IIEF, IIEF-question 9 for ejaculatory function and the MSHQ-EjD (1 centre). Uroflowmetry, PVR and PSA records were also collected.

An independent urologist adjudicated all reported AEs. Device or procedure related AEs were evaluated using a Clavien-Dindo classification.

Study population issues: Mean prostate volume was 48.6 (19.5 to 110.4) cm³ and mean IPSS was 21.6 (13 to 35). There were 32% (21-65) of men with moderate LUTS (IPSS \leq 18) and 68% (44/65) with severe LUTS (IPSS \geq 19). There were 48% (31-65) of men with history of erectile dysfunction.

The mean number of water vapour injections was 4.6 (range 2 to 9). The median lobe was treated in 14 patients with a mean of 1.8 (range 1 to 3) water vapour injections.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Other issues: There were 4 patient receiving BPH medication 1 to 4 months after RFTT for relief of intermittent or residual LUTS. Data from this study was reported in 3 different publications.

Key efficacy and safety findings

Efficacy

n=65 men

Outcome after RFTT including MRI imaging of the prostate

| Variable | Time | n | Mean (Range) | Mean Variation | Mean % variation |
|--|----------|----|----------------------|----------------|------------------|
| Whole prostate volume (cm ³) | 1 week | 44 | 61.2 (20.4 to 133.2) | | |
| | 1 month | 42 | 52.7 (15.4 to 118.4) | -8.5 | -14% |
| | 3 months | 41 | 47 (15.3 to 115.4) | -14.2 | -23% |
| | 6 months | 40 | 43.5 (16 to 116.6) | -17.7 | -29% |
| Transition zone volume (cm ³) | 1 week | 44 | 36.3 (9.1 to 87.8) | | |
| | 1 month | 42 | 29.8 (8.4 to 80.3) | -6.5 | -18% |
| | 3 months | 41 | 25.1 (6.8 to 79.4) | -11.2 | -31% |
| | 6 months | 40 | 22.5 (6.6 to 79.3) | -13.8 | -38% |
| Gadolinium defects volume (cm ³) | 1 week | 44 | 8.2 (0.5 to 24) | | |
| | 1 month | 42 | 3.4 (0.3 to 11.3) | -4.8 | -59% |
| | 3 months | 41 | 0.7 (0 to 2.6) | -7.5 | -92% |
| | 6 months | 40 | 0.4 (0 to 3.7) | -7.8 | -95% |

Paired PSA levels at baseline and during 6 months follow-up

| PSA (ng/mL) | Time point Mean±SD | | | |
|-------------------|--------------------|---------|----------|----------|
| | Week 1 | 1 month | 3 months | 6 months |
| n (paired values) | 36 | 20 | 41 | 41 |
| Baseline | 3.5±3.6 | 4.3±4.1 | 3.3±3.4 | 3.3±3.4 |
| Follow-up | 18.7±16 | 5.6±3.3 | 3.3±3.8 | 3.1±3.0 |
| Change | 15.2±15.3 | 1.2±3.5 | -0.0±2.5 | -0.2±1.9 |
| P value | <0.001 | 0.131 | 0.971 | 0.513 |

Proportion of patients with IPSS improvement after RFTT

| Posttreatment | IPSS change from baseline n/N (% of patients) | | | |
|---------------|--|-------------|-------------|-------------|
| | ≥25% | ≥50% | ≥3 points | ≥5 points |
| 3 months | 86% (53/62) | 73% (45/62) | 90% (56/62) | 82% (51/62) |
| 6 months | 87% (55/63) | 73% (46/63) | 91% (57/63) | 84% (53/63) |
| 1 year | 83% (48/58) | 67% (39/58) | 88% (51/58) | 81% (47/58) |
| 2 years | 84% (36/43) | 61% (26/43) | 93% (40/43) | 79% (34/43) |

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

Baseline, follow-up and change in each outcome measure after RFTT

| Outcome measure | 1 month | 3 months | 6 months | 12 months | 24 months |
|--|-----------|-----------|------------|------------|------------|
| IPSS | | | | | |
| n (paired volumes) | 64 | 62 | 62 | 58 | 43 |
| Baseline | 21.6±5.5 | 21.7±5.5 | 21.5±5.6 | 21.7±5.7 | 21.7±5.3 |
| Follow-up | 14.8±8.4 | 8.3±5.8 | 8.5±7 | 9.2±6.5 | 9.6±6.5 |
| Change | -6.8±10 | -13.4±7.6 | -13.1±8.6 | -12.5±7.6 | -12.1±7.9 |
| % change, p-value | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |
| IPSS QoL | | | | | |
| n (paired volumes) | 64 | 62 | 62 | 58 | 43 |
| Baseline | 4.3±1.1 | 4.3±1.1 | 4.3±1.1 | 4.4±1.1 | 4.4±1.2 |
| Follow-up | 2.9±1.8 | 1.5±1.4 | 1.6±1.6 | 1.7±1.4 | 1.8±1.4 |
| Change | -1.5±2 | -2.8±1.6 | -2.7±2 | -2.7±1.6 | -2.6±1.7 |
| % change, p-value | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |
| BPHII | | | | | |
| n (paired volumes) | 62 | 61 | 59 | 56 | 42 |
| Baseline | 6.8±2.9 | 6.8±2.9 | 6.8±2.9 | 6.9±2.8 | 7.1±2.7 |
| Follow-up | 5.5±3.6 | 2.2±2.4 | 2±2.6 | 2±2.3 | 2.3±2.5 |
| Change | -1.2±4.4 | -4.7±3.2 | -4.8±3.7 | -4.9±3 | -4.8±3.5 |
| % change, p-value | p=0.034 | p<0.001 | p<0.001 | p<0.001 | p<0.001 |
| Qmax (ml/s) | | | | | |
| n (paired volumes) | 63 | 61 | 60 | 57 | 39 |
| Baseline | 7.9±3.2 | 8.1±3.2 | 8±3.1 | 8.1±3.3 | 8.3±2.8 |
| Follow-up | 9.9±3.9 | 12.8 | 12.3±5.3 | 12.7±6.3 | 12±6.2 |
| Change | 2±4.5 | 4.7±6.4 | 4.3±5.5 | 4.6±6.4 | 3.7±6.5 |
| % change, p-value | p<0.001 | p<0.001 | p<0.001 | p<0.001 | p=0.001 |
| PVR | | | | | |
| n (paired volumes) | 62 | 60 | 58 | 55 | 38 |
| Baseline | 92.1±77.9 | 89.5±77.3 | 87.3±74.2 | 92.2±78.4 | 78.5±65.8 |
| Follow-up | 67.1±64.4 | 59.6±66.4 | 65.9±88.5 | 64.5±72.3 | 62.8±83.9 |
| Change | -25±92.3 | -29.9±78 | -21.4±88.3 | -27.6±82.9 | -15.6±93.1 |
| % change, p-value | p=0.037 | p=0.004 | p=0.071 | p=0.017 | p=0.307 |
| IIEF-15 | | | | | |
| n (paired volumes) | 60 | 58 | 59 | 55 | 31 |
| Baseline | 13.3±12 | 12.8±11.8 | 13.5±12 | 12.6±11.7 | 11.8±12.4 |
| Follow-up | 10.3±11.6 | 14.5±11.9 | 15.4±12 | 14.1±11.8 | 15.5±11.5 |
| Change | -3±9.8 | 1.7±10.1 | 1.9±8.9 | 1.5±8.7 | 3.6±6.8 |
| % change, p-value | p=0.019 | p=0.201 | p=0.102 | p=0.210 | p=0.006 |
| IIEF-15 question 9 (ejaculatory function) | | | | | |
| n (paired volumes) | 64 | 62 | 60 | 58 | 33 |
| Baseline | 2.2±2.2 | 2.2±2.2 | 2.2±2.2 | 2.1±2.2 | 2.1±2.3 |
| Follow-up | 1.8±2.3 | 2.9±2.3 | 2.6±2.3 | 2.6±2.3 | 2.7±2.2 |
| Change | -0.4±2.2 | 0.7±2.3 | 0.5±1.9 | 0.4±1.7 | 0.5±1.8 |
| % change, p-value | p=0.151 | p=0.02 | p=0.061 | p=0.053 | p=0.095 |
| MSHQ-EJD function | | | | | |
| n (paired volumes) | 14 | 14 | 13 | 12 | 8 |
| Baseline | 5.9±4.8 | 5.9±4.8 | 5.5±4.7 | 5.3±4.9 | 4.6±5.2 |
| Follow-up | 5.6±6.1 | 7.1±5.0 | 8±4.5 | 5±4.7 | 7±4.8 |
| Change | -0.2±3.9 | 1.2±4.6 | 2.5±4.9 | -0.3±5.8 | 2.4±5.2 |
| % change, p-value | p=0.841 | p=0.339 | p=0.585 | p=0.884 | p=0.234 |
| MSHQ-EJD bother | | | | | |
| n (paired volumes) | 14 | 14 | 13 | 12 | 8 |

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

| | | | | | | |
|-------------------|----------|----------|--------------|----------|---------|--|
| Baseline | 2.3±2.3 | 2.3±2.3 | 2.5±2.3 | 2.3±2.2 | 2.6±2.2 | |
| Follow-up | 0.8±0.9 | 0.9±1.1 | 1±0.9 | 0.9±0.8 | 0.8±2.5 | |
| Change | -1.5±2.7 | -1.4±2.4 | -1.5±2.5 | -1.3±2.3 | -1.9±2 | |
| % change, p-value | -p=0.057 | p=0.057 | -61%, p=0.06 | p=0.071 | p=0.035 | |

Safety

There were no perioperative serious device or procedure related AEs.

| | Events | Patients n (%) | Number of AEs by Follow-up | | | |
|---|------------|----------------|----------------------------|---------------------|-------------------|------------------|
| | | | 0 to 1 month | >1 to 3 months | >3 to 12 months | >12 to 24 months |
| Serious AEs related | 3* | 1/65 | 1 | 0 | 0 | 0 |
| Serious AEs unrelated | 14 | 14% (9/65) | 4 | 1 | 6 | 3 |
| Related non-serious AEs | | | | | | |
| Urinary retention | 24 | 34% (22/65) | 21 | 2 | 1 | 0 |
| Dysuria | 14 | 22% (14/65) | 9 | 4 | 1 | 0 |
| Urinary urgency | 14 | 20% (13/65) | 10 | 4 | 0 | 0 |
| UTI suspected | 13 | 20% (13/65) | 8 | 4 | 1 | 0 |
| Haematuria | 10 | 14% (9/65) | 10 | 0 | 0 | 0 |
| Poor stream | 10 | 14% (9/65) | 6 | 3 | 1 | 0 |
| Pain/discomfort | 7 | 11% (7/65) | 5 | 2 | 0 | 0 |
| Nocturia | 6 | 8% (5/65) | 5 | 1 | 0 | 0 |
| Urinary frequency | 5 | 6% (4/65) | 4 | 1 | 0 | 0 |
| Urethral secretion (without haematuria or stones) | 3 | 5% (5/65) | 2 | 0 | 1 | 0 |
| Fever | 3 | 5% (3/65) | 3 | 0 | 0 | 0 |
| Terminal dribbling | 2 | 3% (2/65) | 1 | 0 | 1 | 0 |
| Scrotal pain/discomfort | 2 | 3% (2/65) | 1 | 1 | 0 | 0 |
| Urinary incontinence | 2 | 2% (1/65) | 1 | 0 | 0 | 0 |
| Total Non-serious | 115 | | 75% (86/115) | 19% (22/115) | 4% (6/115) | 0% |

In no case was a lesion seen between the prostate and the rectal wall. The mean closest distance to the rectal wall was 15.4 mm (range 5.2 to 62.2 mm). Treatment defects were within 1 to 4 mm of the urethra and the prostatic urethra mucosa appeared intact on the gadolinium-enhanced areas of coronal view.

Some patients 55% (36/65) were catheterized before discharge at the discretion of the investigator (precautionary catheter use; 15), or for inadequate voiding (14), haematuria (6), or dysuria (1), events often associated with rigid cystoscopy. The median duration of catheter use was 4.1 days. An additional 11 patients (17%) were catheterized after discharge for a median of 3.8 days related to urinary retention or travel convenience.

*In 3 patients, the treatment was delivered outside the prostate target. Subsequent 1, 3 and 6-month follow-up imaging showed progressive and complete resolution of the extraprostatic treatment

Abbreviations used: AEs, adverse events; BPH, benign prostatic hyperplasia; BPHII, benign prostatic hyperplasia impact index; IIEF-15, international index of erectile function; IPSS, international prostate symptom score; LUTS, lower urinary tract symptoms; MSHQ-EJD, male sexual health questionnaire for ejaculatory function; OAB, overactive bladder; PSA, prostate specific antigen; PVR, post-void residual urine volume; Qmax, peak urinary flow; QoL, quality of life; RFTT, convective radiofrequency thermal treatment; SD, standard deviation; TURP, transurethral resection of the prostate; UTI, urinary tract infection.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

Study 9 Gupta N (2018)

Details

| | |
|--|---|
| Study type | Comparative study |
| Country | USA |
| Recruitment period | Water vapour thermal therapy group: 2013-14 (see study 1) Medical therapy groups: not reported |
| Study population and number | n= 1,269 (129 thermal therapy, 367 doxazosin, 390 finasteride, 383 combination [doxazosin + finasteride] therapy) men with benign prostatic hyperplasia |
| Age and sex | Thermal therapy: mean 63 years Doxazosin: mean 62 years Finasteride: mean 63 years Combination: mean 63 years |
| Patient selection criteria | Thermal therapy group: patients from the treatment arm of an RCT of thermal therapy (study 1) Medical therapy groups: patients from the Medical therapy of prostatic symptoms (MTOPS) study. Men with a prostate volume of 30 to 80 cc and an I-PSS (International Prostate Symptom Score) score of 13 or more. |
| Technique | Thermal therapy using the Rezum device. Medical therapy groups: doxazosin 4 to 8 mg alone, finasteride 5 mg alone or combination therapy with doxazosin and finasteride. Medications were ingested daily and there were provisions for dose modifications based on tolerability per protocol. |
| Follow-up | 3 years |
| Conflict of interest/source of funding | The study was supported by NxThera. One of the authors had a financial interest or other relationship with NxThera. |

Analysis

Study design issues:

- The outcome assessments included changes with time in I-PSS, BPHII, Qmax and PVR and clinical progression of BPH as defined in the MTOPS study, including the first occurrence of a 4-point or greater increase in I-PSS over baseline or urological events attributable to BPH progression.
- 95% (129/136) of men randomised to the active arm in the thermal therapy RCT were included. Six men were censored because their baseline was higher than the maximum I-PSS of 30 permitted in MTOPS.
- Of the original 3,047 MTOPS patients 1,140 (37.4%), excluding the placebo group, remained after censoring those with a baseline I-PSS score below 13, prostate size less than 30 cc or a missing baseline variable needed to estimate propensity scores.

Study population issues:

- Propensity scores were used to adjust for potential confounders by weighting the MTOPS cohorts such that baseline characteristics (I-PSS, QOL, prostate volume and other variables) would be balanced between the water vapour thermal therapy group and each weighted MTOPS group.
- There were statistically significant differences at baseline between the thermal therapy and the doxazosin groups for BPHII and body mass index ($p<0.05$).

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

Key efficacy and safety findings

Efficacy

Number of patients analysed: 1,269 (129 thermal therapy, 367 doxazosin, 390 finasteride, 383 combination [doxazosin + finasteride] therapy) – cohort with propensity score weighting

Rates and cumulative incidence of BPH/LUTS clinical progression during 3-year follow-up (cohort without propensity score weighting)

| BPH | Thermal therapy (n=129) | Doxazosin (n=368) | Finasteride (n=394) | Combination (n=384) |
|--|----------------------------|----------------------|------------------------|------------------------|
| Rate per 100 person-years | | | | |
| Clinical progression* | 0.3 | 1.7 | 1.5 | 1.7 |
| I-PSS 4-point or greater increase | 0.3 | 1.0 | 0.9 | 1.2 |
| Retention due to BPH | 0 | 0.4 | 0.1 | 0.1 |
| Incontinence | 0 | 0.3 | 0.5 | 0.4 |
| Recurrent UTI or urosepsis | 0 | 0 | 0 | 0 |
| Invasive therapy† | 0 | 0.4 | 0.2 | 0.3 |
| Number of 3-year cumulative events (%) | | | | |
| Clinical progression* | <1% (1/129) | 5% (18/368) | 4% (16/394) | 5% (18/384) |
| I-PSS 4-point or greater increase | <1% (1/129) | 3% (11/368) | 3% (10/394) | 3% (13/384) |
| Retention due to BPH | 0 | 1% (4/368) | <1% (1/394) | <1% (1/384) |
| Incontinence | 0 | <1% (3/368) | 1% (5/394) | 1% (4/384) |
| Recurrent UTI or urosepsis | 0 | 0 | 0 | 0 |
| Invasive therapy† | 0 | 1% (5/368) | <1% (2/394) | 1% (4/384) |

* Definition from MTOPS trial used, including any of 4-point or greater I-PSS increase from baseline, acute urinary retention, UTI, urosepsis or incontinence; or serum creatinine increase attributable to BPH of at least 1.5 mg/dl to at least 50% above baseline.

† Definition from MTOPS trial used, including need for any invasive therapy such as transurethral prostatectomy, transurethral incision of prostate, transurethral microwave therapy, laser therapy, stenting or open prostatectomy.

I-PSS (propensity score weighted analysis) at 3 and 36 months

| | Rezum | | Doxazosin | | | Finasteride | | | Doxazosin + Finasteride | | |
|-------------------------------|--------------------|-----------|--------------------|---------------------------|---------|--------------------|---------------------------|---------|-------------------------|---------------------------|---------|
| | Number of patients | Change | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value |
| Mean±SD 3 months | 128 | -11.1±7.4 | 332 | -8.5±6.4 | - | 339 | -5.8 ±4.8 | - | 330 | -9.6 ± 6.5 | - |
| Mean 3-month change (95% CI) | - | - | - | 2.6 (1.2 to 3.9) | <0.001 | - | 5.2 (4.0 to 6.4) | <0.001 | - | 1.4 (0.0 to 2.8) | 0.05 |
| Mean±SD 36 months | 94 | -10.7±7.2 | 302 | -8.9±6.5 | - | 309 | -8.5±4.6 | - | 323 | -11.0 ± 7.5 | - |
| Mean 36-month change (95% CI) | - | - | - | 1.8 (0.36 to 3.2) | 0.02 | - | 2.2 (1.0 to 3.4) | <0.001 | - | -0.27 (-1.9 to 1.4) | 0.73 |

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

BPHII (propensity score weighted analysis) at 3 and 36 months

| | Rezum | | Doxazosin | | | Finasteride | | | Doxazosin + Finasteride | | |
|-------------------------------|--------------------|----------|--------------------|---------------------------|------------------|--------------------|---------------------------|-------------|-------------------------|---------------------------|---------|
| | Number of patients | Change | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value |
| Mean±SD 3 months | 128 | -3.3±3.5 | 331 | -2.6±2.2 | - | 339 | -2.7 ±2.4 | - | 328 | -3.4 ± 2.5 | - |
| Mean 3-month change (95% CI) | - | - | - | 0.66 (0.13 to 1.2) | 0.02 | - | 0.64 (0.08 to 1.2) | 0.03 | - | -0.12 (-0.71 to 0.48) | 0.69 |
| Mean±SD 36 months | 94 | -3.6±3.3 | 302 | -2.4±2.5 | - | 309 | -3.1±2.3 | - | 322 | -3.1 ± 2.3 | - |
| Mean 36-month change (95% CI) | - | - | - | 1.2 (0.63 to 1.8) | <0.001 | - | 0.49 (-0.09 to 11) | 0.10 | - | 0.54 (-0.04 to 1.1) | 0.07 |

Qmax (ml/s, propensity score weighted analysis) at 3 and 36 months

| | Rezum | | Doxazosin | | | Finasteride | | | Doxazosin + Finasteride | | |
|-------------------------------|--------------------|---------|--------------------|---------------------------|-------------|--------------------|---------------------------|------------------|-------------------------|---------------------------|------------------|
| | Number of patients | Change | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value |
| Mean±SD 3 months | 119 | 6.5±7.3 | 315 | 5.0±5.8 | - | 333 | 2.8 ±6.8 | - | 325 | 3.0 ± 4.4 | - |
| Mean 3-month change (95% CI) | - | - | - | -1.5 (-2.8 to -2.0) | 0.02 | - | -3.6 (-5.1 to -2.1) | <0.001 | - | -3.5 (-4.6 to -2.3) | <0.001 |
| Mean±SD 36 months | 78 | 3.9±4.7 | 281 | 3.5±5.7 | - | 306 | 1.9±5.5 | - | 310 | 3.2 ± 6.5 | - |
| Mean 36-month change (95% CI) | - | - | - | -0.43 (-1.7 to 0.87) | 0.52 | - | -2.1 (-3.3 to -0.77) | 0.002 | - | -0.75 (-2.2 to 0.73) | 0.31 |

PVR (ml, propensity score weighted analysis) at 3 and 36 months

| | Rezum | | Doxazosin | | | Finasteride | | | Doxazosin + Finasteride | | |
|-------------------------------|--------------------|------------|--------------------|---------------------------|-------------|--------------------|---------------------------|---------|-------------------------|---------------------------|---------|
| | Number of patients | Change | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value | Number of patients | Estimated Change vs Rezum | p Value |
| Mean±SD 3 months | 127 | -10.6±68.7 | 329 | -27.5±66.5 | - | 345 | -0.42 ±72.1 | - | 337 | -18.6 ± 69.4 | - |
| Mean 3-month change (95% CI) | - | - | - | -16.9 (-30.6 to -3.4) | 0.02 | - | 10.2 (-4.7 to 25.0) | 0.18 | - | -8.0 (-22.7 to 7.0) | 0.27 |
| Mean±SD 36 months | 90 | -23.8±64.6 | 291 | -12.7±79.1 | - | 312 | -14.9±67.8 | - | 314 | -12.6 ± 76.7 | - |
| Mean 36-month change (95% CI) | - | - | - | 11.5 (-6.0 to 29.0) | 0.20 | - | 10.2 (-5.6 to 25.9) | 0.20 | - | 11.0 (-6.2 to 28.2) | 0.20 |

Abbreviations used: BPH, benign prostatic hyperplasia; BPHII, BPH impact index; CI, confidence interval; I-PSS, international prostate symptom score; LUTS, lower urinary tract symptoms; MTOPS, medical therapy of prostatic symptoms; PVR, post-void residual volume urine; Qmax, peak urinary flow rate; SD, standard deviation; UTI, urinary tract infection; vs, versus.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

Study 10 Mollengarden D (2017)

Details

| | |
|--|---|
| Study type | Retrospective case series |
| Country | US (single centre) |
| Recruitment period | 2013-16 |
| Study population and number | n= 129 men with benign prostatic hyperplasia |
| Age and sex | Mean 67 years |
| Patient selection criteria | All patients were at least 4 months out from treatment. The first 25 patients were part of the Rezūm II study population and met the requisite inclusion and exclusion criteria. The remainder and majority of the patients were selected for treatment based on the provider's clinical judgment. |
| Technique | The Rezūm II trial subpopulation underwent washout periods from all LUTS/BPH medications, otherwise patients were maintained on their medications through the procedure. Patients who were not taking BPH medication were usually started on alpha-blockers before the procedure. Immediately before the procedure, patients had 5 ml of lidocaine jelly instilled into their urethra for about 10 minutes. They then had a transrectal-guided ultrasound modified prostate block with 20 ml of 1% lidocaine. Some patients additionally elected to take 0.25–0.5 mg of oral alprazolam. Patients were discharged home with either a standard urethral catheter or a temporary Spanner Prostatic stent ("Spanner"). Catheters were typically removed within 1 week of the procedure. If the bladder was not emptying sufficiently, the catheter was replaced. If a Spanner was placed, it was typically continued for 2–5 weeks until the inflammatory phase of healing had passed. BPH medications were stopped when adequate recovery was observed. |
| Follow-up | 4 to 12 months |
| Conflict of interest/source of funding | Dr. Roehrborn has been a funded investigator in the randomised controlled REZUM trial. The remaining authors declared that they had no conflict of interests. |

Analysis

Follow-up issues:

- Data were analysed at baseline, 15 to 45 days, 46 to 90 days, and 91 to 180 days after treatment.
- Adverse events were noted with follow up periods of 4 to 12 months. A UTI was defined as a symptomatic patient with a urine culture growing at least 50,000 colony forming units per millilitre of urine.
- All patients successfully completed the procedure. Two patients (1.5%) were lost to follow up and were not included in the analysis.

Study design issues:

- IPSS, Qmax, residual urine volumes, medication usage, and adverse events were monitored.
- A patient questionnaire with 3 questions was attempted over the phone to all patients. It was administered by a resident and medical student who do not work in the surgeon's office.
- Only data obtained after urethral catheter or Spanner removal were included in the analysis. The mean interval values were compared to each patient's baseline value using a two-tailed Student's t-test. p-values for UTI rates among subpopulations were calculated using the two-tailed Fisher's exact test.

Study population issues: Separate analyses comparing the Rezūm II trial population results to the remainder of the cohort were done with no statistically significant differences noted; therefore, the data was presented in whole.

Other issues: There are possibly some minor adding errors in one or two of the figures in the paper.

Key efficacy and safety findings

| Efficacy | | | | Safety | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|-------------------|-------------------|------------------------------|--------|-----|----|---|--|--|--|--|--|------------------------------|--|--|--|--|----------------|---|---|---|----|-----|----|---|------------|----|----|---|----|---|---|---|------------------|----|----|--|--|--|--|--|-------------------|---|----|--|--|--|--|--|------------------------------------|----|---|---|---|----|---|---|---|----|----|----|---|---|---|---|------------------|---|---|--|--|--|--|--|----------|---|----|--|--|--|--|--|----------------------|----|----|--|--|--|--|--|---------------------------|---|---|---|---|---|---|---|---------------------------|---|---|---|---|---|---|---|-----------------------------|---|---|---|---|---|---|---|-----------------------------|---|---|---|---|---|---|---|-------------------------------|---|---|---|---|---|---|---|-------------------------------|---|---|---|---|---|---|---|----------------------------------|---|---|---|---|---|---|---|---------------------------|---|---|---|---|---|---|---|----------------------|---|----|---|---|---|---|---|---------------------------------|---|----|---|---|---|---|---|
| Number of patients analysed: 129 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean changes in IPSS, Qmax, and PVR | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Follow-up | 15–45 days | 46–90 days | 91–180 days | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| IPSS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| N (paired values) | 93 | 101 | 89 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean \pm SD (baseline) | 18.5 \pm 7.4 | 18.6 \pm 7.0 | 18.5 \pm 7.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean \pm SD (follow up) | 11.2 \pm 6.4 | 8.5 \pm 5.9 | 6.9 \pm 5.0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change \pm SD | -7.3 \pm 8.8 | -10.1 \pm 7.7 | -11.6 \pm 7.0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change \pm SD | -26.1 \pm 72.5 | -50.2 \pm 41.8 | -60.0 \pm 28.7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| p-value | <0.001 | <0.001 | <0.001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Qmax (ml/s) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| N (paired values) | 40 | 39 | 43 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean \pm SD (baseline) | 10.0 \pm 3.4 | 10.4 \pm 3.6 | 10.8 \pm 4.6 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean \pm SD (follow up) | 13.2 \pm 5.0 | 16.3 \pm 8.6 | 16.8 \pm 6.9 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change \pm SD | 3.2 \pm 5.0 | 6.0 \pm 8.8 | 5.9 \pm 7.3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change \pm SD | 40.5 \pm 56.2 | 71.5 \pm 101.7 | 71.7 \pm 83.4 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| p-value | <0.001 | <0.001 | <0.001 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PVR | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| N (paired values) | 119 | 115 | 99 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean \pm SD (baseline) | 101.7 \pm 114.4 | 103.5 \pm 119 | 108.0 \pm 129.1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Mean \pm SD (follow up) | 82.4 \pm 85.9 | 71.5 \pm 87.8 | 73.1 \pm 91.0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change \pm SD | -19.3 \pm 104.7 | -32.0 \pm 111.5 | -34.8 \pm 119.7 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| % Change \pm SD | -17.3 | -28.8 | -32.3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| p-value | 0.046 | 0.003 | 0.005 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prostate volume | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Of the 27 patients who had their prostate sizes measured before and 6 or more months after treatment, prostate size decreased from an average of 49.9 ± 17.0 SD ml to 41.0 ± 15.0 SD ml (18% volume reduction from baseline ($p < 0.001$)). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| PSA | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Of the 67 patients with PSA values available before and 6 or more months after treatment, PSA decreased from an average of 2.43 ± 1.91 to 2.08 ± 1.65 SD (14.0% decrease, $p = 0.032$). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BPH medications | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Of the patients who were on an alpha-blocker and/or 5- alpha reductase inhibitor preoperatively, 89.5% (85/95) were off all medications at their latest follow up. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Patient satisfaction | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> Response rate: 64% (83/129) of patients Mean procedural satisfaction: 4.2/5. In total 59% were very satisfied, 18% satisfied, 10% neutral, 8% dissatisfied, and 6% very dissatisfied. Mean result satisfaction: 4/5. In total 40% were very satisfied, 25% satisfied, 14% neutral, 4% dissatisfied, and 10% very dissatisfied. In total 86% of patients would recommend the procedure to a friend in similar circumstances. This number is 92% for patients who received a spanner and 83% in patients who received a urethral catheter after the procedure ($p = 0.49$). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Post-operative drainage rate: 100% | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <ul style="list-style-type: none"> Traditional urethral catheter: 65% (84/129) of patients for an average of 4.4 ± 4.3 (SD) days (range 1–26). Spanner: 35% (45/129) of patients for an average of 19.3 ± 12.6 days (range 1–51). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 11% (5/45) had their device replaced with a urethral catheter. One patient had constant urine leakage and had it exchanged for a urethral catheter. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Two patients accidentally dislodged their Spanner 5 and 6 days after their procedures. Both did not have any device replaced. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Adverse events | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <table border="1"> <thead> <tr> <th></th><th></th><th></th><th colspan="5">Clavien-Dindo classification</th></tr> <tr> <th>Adverse events</th><th>n</th><th>%</th><th>I</th><th>II</th><th>III</th><th>IV</th><th>V</th></tr> </thead> <tbody> <tr> <td>UTI</td><td>22</td><td>17</td><td>0</td><td>22</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Spanner patients</td><td>13</td><td>23</td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>Catheter patients</td><td>9</td><td>14</td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>Cystoscopic LUTS evaluation</td><td>10</td><td>8</td><td>0</td><td>0</td><td>10</td><td>0</td><td>0</td></tr> <tr> <td>Urinary retention following catheter or stent removal</td><td>18</td><td>14</td><td>16</td><td>0</td><td>2</td><td>0</td><td>0</td></tr> <tr> <td>from blood clots</td><td>4</td><td>3</td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>from UTI</td><td>1</td><td><1</td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>from prostate oedema</td><td>13</td><td>10</td><td></td><td></td><td></td><td></td><td></td></tr> <tr> <td>Urethral stricture</td><td>5</td><td>4</td><td>0</td><td>0</td><td>5</td><td>0</td><td>0</td></tr> <tr> <td>Postvoid dribbling</td><td>5</td><td>4</td><td>5</td><td>0</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Urinary incontinence</td><td>5</td><td>4</td><td>5</td><td>0</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Erectile dysfunction</td><td>4</td><td>3</td><td>3</td><td>2</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Retrograde ejaculation</td><td>4</td><td>3</td><td>4</td><td>0</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Additional BPH surgery</td><td>3</td><td>2</td><td>0</td><td>0</td><td>3</td><td>0</td><td>0</td></tr> <tr> <td>Prostate tissue sloughing</td><td>2</td><td>2</td><td>2</td><td>0</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Epididymo-orchitis</td><td>2</td><td>2</td><td>0</td><td>2</td><td>0</td><td>0</td><td>0</td></tr> <tr> <td>Bladder stone</td><td>1</td><td><1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td></tr> <tr> <td>Bladder neck contracture</td><td>1</td><td><1</td><td>0</td><td>0</td><td>1</td><td>0</td><td>0</td></tr> </tbody> </table> | | | | | | | | | | | | | Clavien-Dindo classification | | | | | Adverse events | n | % | I | II | III | IV | V | UTI | 22 | 17 | 0 | 22 | 0 | 0 | 0 | Spanner patients | 13 | 23 | | | | | | Catheter patients | 9 | 14 | | | | | | Cystoscopic LUTS evaluation | 10 | 8 | 0 | 0 | 10 | 0 | 0 | Urinary retention following catheter or stent removal | 18 | 14 | 16 | 0 | 2 | 0 | 0 | from blood clots | 4 | 3 | | | | | | from UTI | 1 | <1 | | | | | | from prostate oedema | 13 | 10 | | | | | | Urethral stricture | 5 | 4 | 0 | 0 | 5 | 0 | 0 | Postvoid dribbling | 5 | 4 | 5 | 0 | 0 | 0 | 0 | Urinary incontinence | 5 | 4 | 5 | 0 | 0 | 0 | 0 | Erectile dysfunction | 4 | 3 | 3 | 2 | 0 | 0 | 0 | Retrograde ejaculation | 4 | 3 | 4 | 0 | 0 | 0 | 0 | Additional BPH surgery | 3 | 2 | 0 | 0 | 3 | 0 | 0 | Prostate tissue sloughing | 2 | 2 | 2 | 0 | 0 | 0 | 0 | Epididymo-orchitis | 2 | 2 | 0 | 2 | 0 | 0 | 0 | Bladder stone | 1 | <1 | 0 | 0 | 1 | 0 | 0 | Bladder neck contracture | 1 | <1 | 0 | 0 | 1 | 0 | 0 |
| | | | Clavien-Dindo classification | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Adverse events | n | % | I | II | III | IV | V | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| UTI | 22 | 17 | 0 | 22 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Spanner patients | 13 | 23 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Catheter patients | 9 | 14 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cystoscopic LUTS evaluation | 10 | 8 | 0 | 0 | 10 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Urinary retention following catheter or stent removal | 18 | 14 | 16 | 0 | 2 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| from blood clots | 4 | 3 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| from UTI | 1 | <1 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| from prostate oedema | 13 | 10 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Urethral stricture | 5 | 4 | 0 | 0 | 5 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Postvoid dribbling | 5 | 4 | 5 | 0 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Urinary incontinence | 5 | 4 | 5 | 0 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Erectile dysfunction | 4 | 3 | 3 | 2 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Retrograde ejaculation | 4 | 3 | 4 | 0 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Additional BPH surgery | 3 | 2 | 0 | 0 | 3 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prostate tissue sloughing | 2 | 2 | 2 | 0 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Epididymo-orchitis | 2 | 2 | 0 | 2 | 0 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Bladder stone | 1 | <1 | 0 | 0 | 1 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Bladder neck contracture | 1 | <1 | 0 | 0 | 1 | 0 | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

Abbreviations used: BPH, benign prostatic hyperplasia; IPSS, international prostate symptom score; LUTS, lower urinary tract symptoms; PVR, post-void residual volume urine; Qmax, peak urinary flow rate; PSA, prostate specific antigen; SD, standard deviation; UTI, urinary tract infection.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

Validity and generalisability of the studies

- There is only 1 randomised study (with sham group crossover to treatment) on the use of RFTT for BPH. This has adequate blinding and follow-up to 3 years. Five years follow-up data is not yet available
- All studies used the same device and technique and the outcome assessment tools were consistently used across studies
- Loss to follow-up did not seem to have a major impact on the studies outcomes.

Existing assessments of this procedure

There were no published assessments from other organisations identified at the time of the literature search.

Related NICE guidance

Below is a list of NICE guidance related to this procedure.

Interventional procedures

- Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 611 (2018). Available from <http://www.nice.org.uk/guidance/IPG611>
- Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. NICE interventional procedure guidance 475 (2014). Available from <http://www.nice.org.uk/guidance/IPG475>

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

- Laparoscopic prostatectomy for benign prostatic obstruction. NICE interventional procedures guidance 275 (2008) Available from <https://www.nice.org.uk/guidance/ipg275>
- Holmium laser prostatectomy. NICE interventional procedure guidance 17 (2003). Available from <http://www.nice.org.uk/guidance/IPG17>
- Transurethral electrovapourisation of the prostate. NICE interventional procedure guidance 14 (2003). Available from <https://www.nice.org.uk/guidance/ipg14>

Medical technologies guidance

- GreenLight XPS for treating benign prostatic hyperplasia. NICE medical technologies guidance 29 (2016). Available from <https://www.nice.org.uk/guidance/mtg29>
- UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. NICE medical technologies guidance 26 (2015). Available from <https://www.nice.org.uk/guidance/mtg26>

NICE guidelines

- Lower urinary tract symptoms in men: management. NICE clinical guideline 97 (2010; last updated: June 2015). Available from <http://www.nice.org.uk/guidance/CG97>

Additional information considered by IPAC

Specialist advisers' opinions

Specialist advice was sought from consultants who have been nominated or ratified by their Specialist Society or Royal College. The advice received is their individual opinion and is not intended to represent the view of the society. The advice provided by Specialist Advisers, in the form of the completed questionnaires, is normally published in full on the NICE website during public consultation, except in circumstances but not limited to, where comments are considered voluminous, or publication would be unlawful or inappropriate. Four Specialist Advisor Questionnaires for transurethral water vapour ablation for IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

lower urinary tract symptoms caused by benign prostatic hyperplasia were submitted and can be found on the [NICE website](#).

Patient commentators' opinions

NICE's Public Involvement Programme sent 38 questionnaires to 1 NHS trust for distribution to patients who had the procedure (or their carers). NICE received 15 completed questionnaires.

The patient commentators' views on the procedure were consistent with the published evidence and the opinions of the specialist advisers. See the [patient commentary summary](#) for more information.

Company engagement

A structured information request was sent to 1 company who manufacture a potentially relevant device for use in this procedure. NICE received 1 completed submission. This was considered by the IP team and any relevant points have been taken into consideration when preparing this overview.

Issues for consideration by IPAC

Ongoing clinical trials:

- NCT02940392 - Rezum FIM Optimization (Rezum FIM), Single group assignment; Dominican Republic; n=15, 5 years follow-up; study start date: February 2012; estimated completion date: June 2018.
- NCT02943070 - Rezum I Pilot Study for BPH (Rezum Pilot), Single group assignment; multicentre (Czech Republic, Dominican Republic and Sweden), n=50, 1 years follow-up; study start date: March 2012; study estimated completion date: December 2018.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

References

1. McVary KT, Gange SN, Gittelman MC et al. (2016a) Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. *Journal of Sexual Medicine* 13(6), 924-33
2. McVary KT, Gange SN, Gittelman MC et al. (2016b) Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Journal of Urology* 195(5), 1529-38
3. McVary KT and Roehrborn CG (2017) Three-year outcomes of the prospective, randomised controlled Rezūm system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology*, doi: 10.1016/j.urology.2017.10.023. [Epub ahead of print]
4. Roehrborn CG, Gange SN, Gittelman MC et al. (2017) Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Journal of Urology* 197(6), 1507-1516
5. Darson MF, Alexander EE, Schiffman ZJ et al. (2017) Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rezum system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Research & Reports in Urology* 9, 159-168
6. Dixon CM, Cedano ER, Pacik D et al. (2015) Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology* 86(5), 1042-7
7. Dixon CM, Cedano ER, Pacik D et al. (2016) Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. *Research & Reports in Urology* 8, 207-216
8. Mynderse LA, Hanson D, Robb RA et al. (2015) Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Validation of Convective Thermal Energy Transfer and Characterization With Magnetic Resonance Imaging and 3-Dimensional Renderings. *Urology* 86(1), 122-7

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

9. Gupta N, Rogers T, Holland B et al. (2018) 3-year treatment outcomes of water vapor thermal therapy (Rezum System) compared to doxazosin, finasteride and combination drug therapy for men with benign prostatic hyperplasia: cohort data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. *Journal of Urology* 27, 27
10. Mollengarden D, Goldberg K, Wong D, and Roehrborn C (2017) Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. *Prostate Cancer & Prostatic Diseases* 27, 27

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Literature search strategy

| Databases | Date searched | Version/files |
|---|---------------|-----------------------------------|
| Cochrane Database of Systematic Reviews – CDSR (Cochrane Library) | 26/04/2018 | Issue 4 of 12, April 2018 |
| Cochrane Central Database of Controlled Trials – CENTRAL (Cochrane Library) | 26/04/2018 | Issue 3 of 12, March 2018 |
| HTA database (Cochrane Library) | 26/04/2018 | Issue 4 of 4, October 2016 |
| MEDLINE (Ovid) | 26/04/2018 | 1946 to Present with Daily Update |
| MEDLINE In-Process & Epubs ahead of print (Ovid) | 26/04/2018 | April 25, 2018 |
| EMBASE (Ovid) | 26/04/2018 | 1974 to 2018 Week 17 |

Trial sources searched Clinicaltrials.gov

- ISRCTN
- WHO International Clinical Trials Registry

Websites searched

- National Institute for Health and Care Excellence (NICE)
- NHS England
- Food and Drug Administration (FDA) - MAUDE database
- Australian Safety and Efficacy Register of New Interventional Procedures – Surgical (ASERNIP – S)
- Australia and New Zealand Horizon Scanning Network (ANZHSN)
- EuroScan
- General internet search

The following search strategy was used to identify papers in MEDLINE. A similar strategy was used to identify papers in other databases.

- 1 Prostatic Hyperplasia/
- 2 (Benign adj4 prostat* adj4 (hyperplasia* or enlarge* or hypertroph* or obstruct*)).tw.
- 3 (BPH or BPO or BPE).tw.
- 4 ((Adenofibromatous* or Adenofibromyomatous* or adenoma* or glandular* or stromal*) adj4 (hyperplasia* or enlarge* or hypertroph* or obstruct*)).tw.

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

© NICE 2018. All rights reserved. Subject to [Notice of rights](#)

- 5 Lower Urinary Tract Symptoms/
- 6 (low* adj4 urin* adj4 tract* adj4 symptom*).tw.
- 7 LUTS.tw.
- 8 Urinary Bladder Neck Obstruction/
- 9 (bladder adj4 (outflow* or outlet* or neck*) adj4 obstruct*).tw.
- 10 BOO.tw.
- 11 Prostatism/
- 12 Prostatism*.tw.
- 13 or/1-12
- 14 Ablation Techniques/
- 15 Thermal Conductivity/
- 16 Laser Therapy/ and "Transurethral Resection of Prostate"/
- 17 ((thermal or heat or vapor or vapour or water or wet) adj4 (energy or conduct* or ablat*)).tw.
- 18 ((vapor or vapour or water or wet) adj4 (thermal* or heat* or fever* or thermo-ablat* or thermoablat* or thermo-therap* or thermotherap* or ablat* or therap* or treat*)).tw.
- 19 or/14-18
- 20 13 and 19
- 21 rezum.tw.
- 22 20 or 21
- 23 Animals/ not Humans/
- 24 22 not 23

IP overview: transurethral water vapour ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Appendix

There were no additional papers identified.